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ABSTRACT OF THE DISSERTATION 
CONJUGATED POLYMERS NANOPARTICLES FOR BIOLOGICAL LABELING 
AND DELIVERY 
by 
Eladio Mendez 
Florida International University, 2015 
Miami, Florida 
Professor Joong Ho Moon, Major Professor 
Cancer remains one of the world’s most devastating diseases, with more than 10 million 
new cases every year.  However,  traditional  treatments  have  proven  insufficient  for 
successful  medical  management  of  cancer  due  to  the  chemotherapeutics’  difficulty  
in achieving therapeutic concentrations at the target site, non-specific cytotoxicity to 
normal tissues, and limited systemic circulation lifetime. Although, a concerted effort has 
been  placed  in  developing  and  successfully  employing  nanoparticle(NP)-based  drug 
delivery  vehicles  successfully  mitigate  the  physiochemical  and  pharmacological 
limitations of chemotherapeutics, work towards controlling the subcellular fate of the 
carrier, and ultimately its payload, has been limited. Because efficient therapeutic action 
requires drug delivery to specific organelles, the subcellular barrier remains critical 
obstacle to maximize the full potential of NP-based delivery vehicles. The  aim  of  my  
dissertation  work  is  to  better  understand  how  NP-delivery  vehicles’ structural,  
chemical,  and  physical  properties  affect  the  internalization  method  and subcellular 
localization of the nanocarrier.  
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In this work we explored how side-chain and backbone modifications affect the 
conjugated polymer nanoparticle (CPN) toxicity and subcellular localization. We 
discovered how subtle chemical modifications had profound consequences on the 
polymer’s accumulation inside the cell and cellular retention. We also examined  how 
complexation  of  CPN  with  polysaccharides  affects  uptake  efficiency  and  
subcellular localization.  
This  work  also  presents  how  changes  to  CPN  backbone biodegradability  can 
significantly  affect  the  subcellular  localization  of  the  material.  A  series  of  
triphenyl phosphonium-containing  CPNs  were  synthesized  and  the  effect  of  
backbone modifications  have  on  the  cellular  toxicity  and  intracellular  fate  of  the  
material.  A mitochondrial-specific polymer exhibiting time-dependent release is 
reported. Finally, we present a novel polymerization technique which allows for the 
controlled incorporation of electron-accepting benzothiadiazole units onto the polymer 
chain. This facilitates tuning CPN emission towards red emission.  
The  work presented  here,  specifically,  the  effect  that  side-chain  and  structure,  
polysaccharide formulation  and  CPN  degradability  have  on  material’s  uptake  
behavior,  can  help maximize the full potential of NP-based delivery vehicles for 
improved chemotherapeutic drug delivery. 
.  
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CHAPTER I 
 
INTRODUCTION TO NANOPARTICLE-BASED DRUG 
DELIVERY SYSTEMS   
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1.1 Challenges in Cancer Therapy 
Cancer remains one of the world’s most devastating diseases, with more than 10 million 
new cases every year.  However, as a result of improved understanding of tumor biology, 
improved diagnostic devices and treatments, mortality rates have recently begun to 
decrease.1 Current clinical therapy for cancer includes a combination of chemotherapy, 
radiotherapy, and surgery, among others.2 However, these traditional treatments have 
proven insufficient for successful medical management of cancer patients because of the 
undesired physiochemical and pharmacological properties for the chemotherapeutics 
often employed.2 These chemotherapeutics exhibit narrow therapeutic index (TI)  
because of their difficulty in achieving therapeutic concentrations at the target site, non-
specific cytotoxicity to normal tissues, limited systemic circulation lifetime and problems 
associated with the physical properties of the drugs, such as low in vivo solubility. At the 
cellular level, non-specific cellular uptake and undesirable subcellular distributions 
further reduce the chemotherapeutics’ TI.  
1.2 Biological Barriers to Effective Drug Delivery 
There are several biological barriers that must overcome if therapeutic concentrations of 
the drug are to be effectively delivered to target tumor sites. These barriers can be 
organized into three distinct levels: a physiological, cellular, and subcellular barrier. 
Each poses a different challenge for effective drug delivery. 
At the physiological level, most drugs will undergo rapid systemic clearance preventing 
them from staying in circulation long enough to reach the tumor site. This systematic 
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clearance results in the drug’s degradation in plasma, rapid mononuclear phagocyte 
system (MPS) uptake, and renal filtration out of the organism. At the cellular level, the 
cancer cell’s phospholipid membrane presents a major barrier to cellular entry. 
Although drugs enter cells in various ways, many rely on passive transport such as 
diffusion or channel proteins to facilitate crossing the cell membrane. Passive transport 
limits the drug internalization once equilibrium between intracellular and extracellular 
space is reached. Additionally, the presence of membrane bound drug-efflux pumps, 
which actively vacuum drug molecules out of the cell, further decreases drug 
internalization into the cell.3 Finally, upon internalization into the cell, the distribution of 
the drug within the subcellular organelles plays a key role in the effectiveness of the 
drug.  For therapeutic action to take place, most drugs require them to reach specific 
organelles.  Depending on the entry pathways and subcellular trafficking, internalized 
materials will be trafficked into different organelles, which will significantly influence 
the overall efficiency of the drug.4 Successful drug delivery to the target organelle 
requires all three biological barriers to be overcome which results in a high exclusivity 
towards a wide variety of molecules. In recent years, two main approaches have been 
adopted for chemotherapeutics to overcome these biological barriers.  
One approach has focused on designing and developing new derivatives of 
chemotherapeutics exhibiting improved physiochemical and pharmacological 
properties.5 The drug discovery-based approach has had limited success, as even small 
modifications can often change the function and bioactivity and pharmacokinetics of the 
parent drug. The other approach has focused on modifying the existing 
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chemotherapeutic agents using drug delivery technologies.6 As a result, 
nanoparticle(NP)-based delivery systems have emerged as a promising alternative that 
can overcome many of the limitations of direct drug modification and offer a platform 
which can be modified for the intracellular delivery of cargos with varying charge, size, 
and molecular weight.7  
1.1.2 Nanoparticle-based Drug Delivery 
The requirements for a NP-based drug delivery system to be successful include:  
compatibility with the drug to be delivered, high drug loading efficiency, target-cell 
specificity, sustained systemic circulation, and a controllable drug release profile. Because 
they usually exhibit particle sizes 50-200 nm, NP-based delivery systems are often termed 
“nanocarriers.” Ideally, these nanocarriers should be inexpensive, reproducibly 
synthesized, and exhibit non-toxic biodegradation upon drug release. To tackle these 
material needs, a number of platforms have been synthesized and explored as possible 
delivery vehicles; these include naturally-derived polymers8, liposomes9, and synthetic 
polymers10, among others.   
Naturally-derived polymers include bio-polymers like chitosan, hyaluronic acid, cellulose, 
fibrin, collagen, and gelatin.8 These polymers offer good biocompatibility that may 
positively support cell adhesion and function, and most exhibit biodegradable linkages 
that further lower toxicity. However, naturally derived polymers also have displayed 
immunogenicity and offer decreased control over their mechanical properties, 
inconsistency between batches, and high cost due to limited supply.   
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Liposomes are spherical lipid vesicles consisting of a bilayered lipid membrane, which 
can be prepared synthetically or from natural sources.9 These materials allow for the 
surface charge to be negative, neutral, or positive depending on the lipid head group 
composition, which has been shown to influence the NP stability, bio-distribution, as well 
as the uptake by targeted cells.11 As a result of their biodegradability and biocompatibility 
there are several liposomes and lipid-based products currently approved for clinical use in 
the U.S.12. However, liposomes have exhibited particle stability issues, payload 
incompatibility leading to low drug entrapment, as well as poor particle size control.  
Synthetic polymers, which include polyethylene and polystyrene, polyacrylates and 
polyesters, are synthetically-made polymers offering wide variety of variations to main 
and side-chains.10 They offer good biocompatibility, inexpensive and reproducible 
synthetic methods compatible with large scale production, controllable biodegradation, 
and improved drug release profiles. Additionally, incorporation of various functional 
groups can be synthesized to improve compatibility with the specific drugs to be 
delivered. Because of these desirable properties, this class of materials has been 
extensively explored to encapsulate drugs in colloidal systems.  
1.2.1. Pharmacokinetics and Passive Targeting 
To achieve more efficient tumor targeting, drugs must overcome the physiological level 
barrier caused by the rapid drug clearance via MPS uptake and renal filtration.  A 
simple, widely used technique involves coating therapeutics with a layer of polyethylene 
glycol (PEG), a synthetic hydrophilic polymer that has been shown to retard MPS 
recognition and increase circulation time by forming a hydration layer that inhibits 
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hydrophobic and electrostatic interactions with plasma proteins.13  Incorporation of PEG 
to drugs results in a pseudo-delivery vehicle layer which results in improved drug 
solubility, extended circulation life, increased drug stability, and enhanced protection 
from proteolytic degradation. These pharmacokinetic changes result in more constant 
and sustained plasma concentrations, which lead to increases in clinical effectiveness 
when the desired effects are concentration-dependent. Incorporation of other polymers 
such as N-(2-hydroxypropyl)meth-acrylamide (HPMA) have shown similar 
enhancements to the circulation time.14  
Nanocarriers exhibit similar pharmacokinetic enhancements by passively targeting 
cancer tumors in vivo. Passive targeting  is achieved by the enhanced permeability and 
retention (EPR) effect that arises from the increased permeability of tumor blood 
vessels, a characteristic of rapid and defective angiogenesis. Enhanced retention in the 
interstitial fluid surrounding the tumor is achieved due to dysfunctional lymphatic 
drainage often seen in tumor tissues. The EPR effect enables NPs to accumulate in 
tumor tissue much more readily than they do in healthy tissues, which results in lower 
toxicity to normal tissues. NPs with sizes of up to 400 nm have been reported to exhibit 
EPR, however, particles with diameters of less than 200 nm have been reported to be 
more effective.15  Because EPR relies on the increased permeability of tumor blood 
vessels, passive tumor accumulation is severely diminished in poorly vascularized 
tumors.  
Although the intrinsic EPR effect exhibited by NP-based delivery is an elegant solution 
to the physiological barrier of drug delivery, its effect on the cellular and subcellular 
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pathways. Endocytosis is an energy-dependent process by which cells internalize a 
variety of macromolecules via membranous vesicles.16 Upon interaction with the cell 
membrane, NPs are mainly internalized via adsorptive or receptor-mediated 
endocytosis. In adsorptive endocytosis, molecules non-specifically interact with generic 
complementary binding sites such as negatively charged heparin sulfate proteoglycans 
and hydrophobic membrane lipids. In receptor-mediated endocytosis, ligands bind to 
receptors on the cell surface and are internalized by endosomal vesicles. By 
incorporating ligand moieties onto the nanocarrier, various researchers have made a 
concerted effort to enhance the cellular uptake of NPs.17 The active targeting of cellular 
membrane receptors which are up regulated or uniquely expressed cancer cells ensures 
that the nanocarriers are preferentially localized and internalized into cancer tissues.  
Early attempts towards active targeting encompassed combining the unique targeting 
capabilities of monoclonal antibodies with cancer drugs. However, as a consequence of 
the large size of antibodies, simple incorporation often results in poor size control and 
increased immune response.18  These limitations led to the emergence of alternative 
targeting ligands such as fragment antigen-binding (Fab) antibodies and growth factors 
that target overexpressed receptors in cancer cells.19 Additionally, numerous studies 
have reported covalent attachment of targeting ligands for nutrients whose receptors are 
overexpressed, such as peptides and carbohydrates, to NP surfaces. 17 The small physical 
dimension of these ligands enables for NP incorporation in high density without 
compromising the particle’s circulation time or eliciting an immune response.18 High 
ligand density results  in improved internalization as the efficiency of receptor-mediated 
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undergo rapid maturation to lysosomes.22,23 Nanoparticle accumulations in lysosomal 
compartments often lead to enzymatic degradation and/or recycling back to the cell 
surface, even for systems that take advantage of active targeting by covalent attachment 
of targeting ligands as they undergo receptor-mediated endocytosis. Therefore, 
endocytosis poses a major barrier for drug delivery as therapeutic compounds that are 
transported via these acidic organelles may be inactivated and significantly reduced in 
concentration before reaching their site of action.  
To overcome lysosomal degradation and low delivery efficiency because of  recycling 
out of the cell, a variety of nanocarriers have been developed that respond to the acidic 
environment of the lysosome.24, 25 These pH-responsive carriers aim to increase 
intracellular drug bioavailability by facilitating release out of the endosome or 
enhancing drug transit to the cytoplasm. Synthesis of polymer-drug conjugates 
containing pH-sensitive linkages have been shown to release drugs which then diffuse 
out of the endosome. Unfortunately, reaching appropriate therapeutic concentrations at 
the appropriate subcellular target site can be difficult because of low drug-loading 
capacities. Several cationic polymers have been reported to incorporate “proton 
sponges” that can facilitate endosomal escape.25 These nanocarriers work by 
incorporating functional groups that can effectively buffer the acidic endosomal 
environment, prompting the osmotic swelling, rupture out of the vesicle and into the 
cytoplasm. Similarly, it has been shown that high molecular weight (MW) branched 
amine-containing polymers can damage and destabilize the endosomal membrane.26 
Incorporation of charged pendant, such as carboxylic acids, has been demonstrated to 
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cause NP swelling upon acidification which can rupture the endosome to initiate the 
endosomal escape.25 Finally, fusogenic peptides have been incorporated for the 
endosomal escape of several drug delivery systems.27 These peptides assume coil-like 
structures at neutral pH, and that upon acidification in the endosome, result in a 
conformational change that facilitates penetration out of the endosomal membrane.   
An innovative approach has been to forgo endocytosis entirely via incorporation of cell-
penetrating peptides (CPPs) that enable transport into the cytosol.28 Cell-penetrating 
peptides avoid endosomal internalization by targeting protein transduction domains for 
the transport directly into the cytosol. Incorporation of CPPs onto various 
macromolecules and nanocarriers to assist internalization into mammalian cells.28 The 
promising strategy of using CPPs remains limited by its cost-effectiveness and difficult 
optimization as the mechanism by which these peptides gain direct access to the cell 
cytoplasm remains unclear, due to mechanistic differences from peptide to peptide.  
Although these strategies have been developed and employed to varying degrees of 
success, it becomes clear that to improve drug efficacy, the nanocarrier should not only 
facilitate successful delivery into specific cell types or tissues, but direct the drug to its 
appropriate intracellular destination. 
1.3.1. Nanocarrier Subcellular Localization  
As a result of the significant amount of research has been devoted to addressing the 
physiological and cellular barriers, NPs have emerged as a safer and more effective drug 
delivery option when compared to small molecule chemotherapy. Several nanocarrier 
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platforms have been reported exhibiting long systemic circulation lifetime, passive and 
active targeting ability, cellular internalization through endocytosis, and novel strategies 
designed to facilitate endosomal escape and avoid lysosomal degradation.24-26 However, 
work towards controlling the subcellular fate of the carrier, and ultimately its payload, 
has been limited. Because efficient therapeutic action requires drug require delivery to 
specific organelles, this subcellular barrier remains critical obstacle to maximize the full 
potential of NP-based delivery vehicles.   
1.3.2. Biological Factors Affecting Subcellular Localization 
The main mechanisms for the endocytotic internalization of nanocarriers are 
macropinocytosis, Clathrin-mediated endocytosis, and Caveolae-mediated endocytosis. 23 
Depending on the mechanism, the materials are either sorted towards different organelles 
or recycled out to the extracellular fluid, making the method of internalization the most 
important factor that affecting the subcellular fate of a nanocarrier. 23, 30 
Macropinocytosis (MPC) is an actin-driven endocytosis process that results in the 
formation of macropinosomes, vesicles of irregular size and shape containing no protein 
coat.31 Macropinosomes result from the activation of tyrosine kinase receptors that trigger 
actin-driven invagination of the plasma membrane. In human cells, macropinosomes 
rarely fuses with lysosomes, instead behaving as a distinct vesicle population.30 Although 
contents are often recycled out of the cell, much of the internalized payload can escape 
from macropinosomes and into the cytosol because of the inherently “leaky” nature of 
macropinosomes. Active targeting of MPC can be achieved via incorporation of tyrosine 
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kinases like epidermal growth factor and platelet-derived growth factor onto the 
nanocarrier.  
Clathrin-mediated endocytosis (CME) is a highly regulated and well-studied energy-
dependent receptor-mediated process.30 Transferrin and low-density lipoprotein (LDL) 
receptors will undergo CME upon binding with the appropriate ligand. Once bound, the 
receptor-ligand complex is opsonized in clathrin-coated vesicles, forming vesicles 
ranging in size from 100 to 150 nm in diameter. As the vesicle is internalized, the 
clathrin coat depolymerizes, forming early endosomes. Within these endosomes, the 
contents are sorted to their appropriate cellular destinations, such as lysosomes, the 
Golgi apparatus, the nucleus, or the cell surface.30 Understanding how to efficiently 
manipulate the endosomal sorting remains limited, however, GTPases and Rab proteins 
are known to control this process.  Active targeting of CME can be achieved via 
incorporation of pendant transferrin ligands.  
Finally, Caveolae-Mediated Endocytosis (CvME) is an energy-dependent receptor-
mediated process which results in a non-degradative route of internalization.30-32 
Caveolae are hydrophobic membrane microdomains that are rich in cholesterol and 
glycosphingolipids-binding receptors. Upon binding with the appropriate ligand, the 
receptor-ligand complex is internalized via caveosomes, flask-shaped invaginations of the 
plasma membrane, ranging in size from 50 to 60 nm in diameter and as large as 500 nm 
long, and mediated by membrane-bound caveolin proteins. Once internalized, the 
contents are sorted within the caveosomes for delivery to the endoplasmic reticulum or 
Golgi apparatus. Active targeting of CvME can be achieved via incorporation of 
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cholesterol and glycosphingolipids-rich compounds, which have been shown to be 
preferentially internalized via this endocytotic pathway.  
1.3.3. Control of Subcellular Localization in NP-delivery Systems 
A variety of approaches been reported for NP-based delivery systems which overcome 
the subcellular barrier  presented by the cellular membrane, including cell penetrating 
peptides, targeting ligands, pH dependent nanocarriers, as well as targeting specific 
endocytosis mechanisms, among others. Unfortunately, most of these methods direct the 
payload towards the cytosol as the target site of delivery. Targeting organelles such as the 
mitochondria, pose a further challenge as these organelles necessitate penetration of the 
organelle membranes for effective drug delivery.31 Mitochondrial dysfunction is 
responsible for a variety of human disorders, ranging from neurodegenerative diseases, 
obesity, diabetes, and cancer. Because mitochondria play a key role in cell death 
pathways, targeted drug delivery to this organelle could play a crucial role for future 
cancer treatments.  
Although various targeting moieties exist that effectively target these organelles, 
incorporation of these ligands to macromolecules (e.g. nanocarriers) do not always 
afford organelle-specific targeting. For example, triphenylphosphonium (TPP) 
conjugates readily target the mitochondria because of its amphilicity and cationic 
nature.31 Triphenylphosphonium conjugates have been reported to deliver small-
molecular weight antioxidants and nucleic acid oligomers. However, successful 
mitochondrial localization was only achieved when TPP was incorporated into HPMA 
with an average molecular weight below 5 kDa. Higher molecular HPMA copolymers 
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did not show mitochondrial localization even that after polymer microinjection into the 
cytosol. Other mitochondrial-targeting materials include incorporation of fusogenic 
peptides, such as Mito-8, to quantum dots to afford mitochondria-specificity. Finally, 
materials like dequalinium (DQA), which can form liposome-like aggregates, have been 
reported to exhibit plasmid DNA (pDNA) encapsulation, cellular internalization, and 
pDNA delivery.34 However, DQA does not exhibit improved pharmacokinetics, passive 
or active targeting towards cancer cells.  
1.4. Conjugated Polymer Nanoparticles 
Conjugated polymer nanoparticles (CPNs) and conjugated polyelectrolytes (CPEs) are 
emerging fluorescent synthetic polymers that have been employed towards cellular 
labelling, 35 sensing,36 and delivery37 of biological substances. They are prepared from 
semiconducting conjugated polymers (CP), fluorescent polymers that have been heavily 
utilized in the fields of electronics for light-emitting diodes (LEDs), photonic devices 
components, solar cells, and field-effect transistors (FETs). 38 
Various developments have catalyzed the rapid increase in using CPNs for biological 
applications. Several strategies have been developed to introduce water-solubility and 
overcome the inherent hydrophobicity of the material.39 Well established synthetic 
methods allow for facile modifications of π-electron conjugated backbones and side-
chains to tune fluorescent emission, facilitate controllable biodegradation, incorporate 
targeting units, and improve drug release profiles. Finally, owing to their fluorescent 
nature, CPNs are a unique delivery platform that can facilitate understanding of how 
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chemical structures affect the uptake behavior, bio-distribution and subcellular 
localization of these polymeric vehicles.   
 
Figure 1.3. Common examples of conjugated polymers 
 
1.4.1. Characterization of Endocytosis Mechanisms and Subcellular Localization 
Most methods to study intracellular trafficking of nanomaterials involve either 
inhibition of specific endocytosis mechanisms using pharmacological inhibitors or 
colocalization of nanomaterials with specific endocytosis markers and structures.30 
 Various pharmacological inhibitors can be commercially purchased to specifically 
inhibit certain endocytotic pathways. Clathirin-mediated endocytosis can be 
distinguished by inhibition under a potassium depletion condition or by treating cells 
with a pharmacological inhibitor such as chlorpromazine, which specifically inhibits the 
pit formation by dissociating clathrin lattices. Filipin, nystatin, and methyl-β-
cyclodextrin specifically bind, sequester, or deplete cholesterol, which is involved in the 
CvME. As a tyrosine kinase inhibitor, genistein also blocks CvME.23 Cytochalasin D 
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causes actin de-polymerization in the cytoskeleton, resulting in involvement in both the 
CvME and macropinocytosis.23 Bulk amounts of macromolecules can be taken up by 
cells via macropinocytosis, which involves cell surface ruffling. Since actin 
cytoskeletons affect membrane ruffling, drugs (e.g., amiloride and its derivatives) that 
disrupt the function of the actin cytoskeleton can inhibit macropinocytosis.23 
Phosphatidyl inositol-3-phosphate inhibitor, LY294002 is often used for testing 
macropinocytosis. Because treatments often show cell type-dependent nonspecific 
toxicity, baseline toxicity must first be assessed. The change in nanocarrier uptake upon 
the inhibition of specific endocytotic mechanisms can be measured using flow 
cytometry. Flow cytometry is an instrumental technology that can measure multiple 
physical characteristics of cells, such as fluorescence and scattered light, as they flow in 
a fluid stream through a beam of light. The relative fluorescence intensity per cell can be 
measured to determine nanocarrier uptake.  
Subcellular localization of nanocarriers can be monitored by fluorescent microscopic 
imaging.31 By taking advantage of CPN’s fluorescent nature, the materials can be 
incubated with live cells and can then be co-stained with standard fluorescent dyes 
which are internalized to specific organelles. For instance, treating cells with pHRhodo 
Dextran (10kDa) and BODIPY-TR C5-ceramide-BSA complex will label acidic 
organelles (i.e., endosomes and lysosomes) and Golgi apparatus, respectively. 
Quantitative co-localization information can then be obtained from the micrographs 
using the Pearson's Correlation Coefficient (PCC) method. The PCC method gauges the 
level of overlap by measuring the pixel-by-pixel covariance in the signals of two 
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images. Because the PCC method uses normalized signals by subtracting the mean 
intensity from each pixel's intensity value, PCC is independent of signal levels (i.e. 
probe brightness) and signal offset (i.e. background). PCC values of 0 and 1 correspond 
to uncorrelated and perfectly linear correlated images, respectively. 
1.4.2. CPN Characterization 
Internalization mechanism and subcellular localization are influenced by a variety of the 
CPN’s physical properties, such as molecular weight, particle size, and zeta potential.33 
Therefore, proper characterization of a CPN’s physical properties is paramount to 
accurately correlate the nanocarrier’s physiochemical properties with the endocytosis 
mechanism and subcellular localization.  
Physical characteristics often measured for the CPN include molecular weight, 
polydispersity, and particle size. Polymer molecular weight is typically measured by gel 
permeation chromatography (GPC), a chromatographic technique which separates a 
mixture based on size. Molecular weight and polydispersity index (PDI) can be obtained 
relative to standard samples, typically polystyrene.  Particle size can be measured using 
light scattering techniques such as dynamic light scattering (DLS) or nanoparticle 
tracking analysis (NTA). Both measure fluctuations in scattered light which is a function 
of the Brownian motion experienced by the particle. The Brownian motion is related to 
the hydrodynamic radius through the Stokes-Einstein equation.  
Chemical characterization of the polymers can be measured using spectroscopic 
techniques such nuclear magnetic resonance (NMR) spectroscopy, and various 
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absorption and fluorescence spectroscopic techniques. Proper characterization ensures 
that correlation of chemical moieties, and CPN chemical structure can be properly 
correlated to endocytosis mechanism and subcellular localization. The chemical 
structure of a polymer sample can be ascertained by NMR spectroscopy. Changes of 
magnetic moment of magnetically active nuclei of hydrogen/protons (1H) and carbon 
(13C) are typically obtained. NMR spectra give quantitative information about the 
relative proportion of each proton in the polymer chain, allowing the average frequency 
of each monomer in the polymer chain. The presence of numerous functional groups in 
a polymer sample can be detected using Fourier transform infrared spectroscopy (FTIR). 
The photophysical properties of conjugated polymers are measured typically using UV-
Visible absorption spectroscopy absorption and fluorescence spectroscopy.  
1.5. Scope and Organization 
Nanoparticles are emerging as a safer and more effective drug delivery option as 
compared to small molecule chemotherapy. Delivery of NP vehicles exhibit numerous 
favorable features such as long systemic circulation lifetime, targeting ability, and 
cellular internalization through endocytosis. However, work towards controlling the 
subcellular fate of the carrier, and ultimately its payload, has been limited. Because 
efficient therapeutic action requires drug require delivery to specific organelles, the 
subcellular barrier remains critical obstacle to maximize the full potential of NP-based 
delivery vehicles.  The aim of my dissertation work is to better understand how CPN 
structural, chemical, and physical changes affect the internalization method and 
subcellular localization of the nanocarrier.   
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Understanding how the chemical interactions between CPN and the cellular membrane 
affect the subcellular localization and toxicity is paramount to improving overall 
labelling and delivery efficiency. Chapter 2 details how side-chain and backbone 
modifications affect the CPN toxicity and subcellular localization. Four model polymers 
were synthesized containing differing side-chain and backbone structures, but exhibiting 
similar physical properties (size, charge density). These subtle chemical modifications 
had profound effects on the polymer accumulation inside the cell and cellular retention. 
We demonstrate how CPN toxicity and subcellular localization can be tuned by 
modifying physicochemical properties.  
Chapter 3 details how complexation of CPN with polysaccharides affects uptake 
efficiency and subcellular localization. The effect of siRNA complexation is also 
explored. Interestingly, upon complexation with polysaccharides subcellular localization 
does not change, and cellular uptake decreases. Upon siRNA complexation, cellular 
uptake increases. Therefore, we report how CPN uptake efficiency and subcellular 
localization is affected upon complexation with polysaccharides and nucleic acids.  
Chapter 4 details how changes to CPN backbone structure can significantly affect the 
subcellular localization of the material. A series of triphenyl phosphonium-containing 
CPNs were synthesized and the effect of backbone modifications have on the cellular 
toxicity and intracellular fate of the material were measured. A mitochondrial-specific 
polymer exhibiting time-dependent release is reported.  
Finally, chapter 5 details a novel polymerization technique which allows for the 
controlled incorporation of electron-accepting benzothiadiazole units onto the polymer 
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chain. This facilitates tuning CPN emission towards red emission which is highly 
desirable, as the sensitivity of any in vivo measurements and optical imaging is 
significantly enhanced due to minimal autofluorescence from biological tissues at this 
range. Additionally, this polymer may exhibit different cellular behaviors as the subtle 
chemical changes influence the entry and localizations. 
1.6. References 
1. Siegel R, Ma J, Zou Z, Jemal A. CA: A Cancer Journal for Clinicians 2014, 64, 
9-29.  
2. Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella 
G. Current Pharmaceutical Design 2010, 16, 3-10. 
3. Lei T, Srinivasan S, Tang Y, Manchanda R, Nagesetti A, Fernandez-Fernandez A, 
McGoron  A. Nanomedicine: Nanotechnology, Biology and Medicine 2011, 7, 
324-332.  
4. Sahay G, Alakhova DY, Kabanov AV. Journal Controlled Release 2010, 145, 
182. 
5. Collins I, Workman P, Nature Chemical Biology  2006, 2, 689. 
6. Duncan R. Nature Review Cancer  2006, 6, 688. 
7. Heath JR, Davis ME. Annual Review of Medicine  2008, 59, 251. 
8. Huang S, Fu X. Journal of Controlled Release 2010, 142, 149-159. 
9. Allen TM, Cullis PR. Advanced Drug Delivery Reviews 2013, 65, 36-48. 
10. Liechty, W, Kryscio D, Slaughter B.  Annual Review of Chemical and 
Biomolecular Engineering 2010, 1, 149-173. 
11. Samad, A.; Sultana, Y.; Aqil, M. Current Drug Delivery 2007, 4, 297-305. 
12. Chang H, Cheng M. Journal of Nanomedicine & Biotherapeutic Discovery 2012, 
01. 
13. Wang YY, Lai SK, Suk JS, Pace A, Cone R, Hanes J, Angewandte Chemie 
International. 2008, 47, 9726. 
22 
 
14. Whiteman K,  Subr V, Ulbrich K, Torchilin V. Journal of Liposome 
Research 2001, 11, 153-164. 
15. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K, Journal of  Controlled Release 
2000, 65, 271. 
16. Doherty GJ, McMahon HT. Annual Review of Biochemistry, 2009, 78, 142. 
17. Byrne JD, Betancourt T, Brannon-Peppas L. Advanced Drug Delivery Reviews 
2008, 60, 1615-1626. 
18.  Zolnik B,  González-Fernández Á, Sadrieh N, Dobrovolskaia 
M. Endocrinology 2010, 151, 458-465. 
19. Arruebo M,  Valladares M, González-Fernández Á. Journal of 
Nanomaterials 2009, 1-24. 
20. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology 
2013, 66, 2-25. 
21. Li X, Zhou H, Yang L, Pai-Panandiker AS, Huang X, Yan B. Biomaterials 2011, 
32, 2540-5. 
22. Li W-S, Jiang D-L, Aida T. Angewandte Chemie International Edition. 
2004;43(22):2943-7. 
23. Kou L, Sun J, Zhai Y, He Z. Asian Journal of Pharmaceutical Sciences 2013, 8, 
1-10. 
24. Gao W, Chan JM, Farokhzad OC. Molecular Pharmaceutics 2010, 7, 1913-1920. 
25. Shen Y, Tang H, Radosz M, Van Kirk E, Murdoch WJ. Methods of Molecular 
Biology 2008, 437, 183-216. 
26. Maher MA, Naha PC, Mukherjee SP, Byrne HJ. Toxicology In Vitro 2014, 28, 
1449-60. 
27. Lau WL, Ege DS, Lear JD, Hammer DA, DeGrado WF. Biophysical Journal 
2004, 86, 272-284. 
28. Copolovici DM, Langel K, Eriste E, Langel, Ã. ACS Nano 2014, 8, 1972-1994. 
29. Oh N, Park JH. International Journal of Nanomedicine 2014, 9, 51-63. 
30. Iversen TG, Skotland T, Sandvig K. Nano Today 2011, 6, 176-185. 
31. Kerr MC, Teasdale RD. Traffic 2009, 10, 364-71. 
23 
 
32. Doherty G, McMahon H. Annual Reviews of Biochemistry 2009, 78, 857-902. 
33.  Hoye AT, Davoren JE, Wipf P, Fink MP, Kagan VE. Accounts of Chemical 
Research 2008, 41, 87-97. 
34. Weissig V, Lasch J, Erdos G, Meyer HW, Rowe TC, Hughes, J. Pharmaceutical 
Research 1998, 15, 334-7. 
35. Hide F, DÍaz-GarcÍa MA, Schwartz BJ, Heeger AJ. Accounts of Chemical 
Research. 1997;30(10):430-6. 
36. Günes S, Neugebauer H, Sariciftci NS. Chemical Reviews. 2007;107(4):1324-38. 
37. Torsi L, Dodabalapur A, Rothberg LJ, Fung AWP, Katz HE. Science. 
1996;272(5267):1462-4. 
38. McQuade DT, Pullen AE, Swager TM. Chemical Reviews. 2000;100(7):2537-74. 
39. Feng L, Zhu C, Yuan H, Liu L, Lv F, Wang S. Chemical Society Reviews 2013, 
42, 6620-6633.  
24 
 
 
CHAPTER II 
 
 
SIDE CHAIN AND BACKBONE STRUCTURE-DEPENDENT SUBCELLULAR 
LOCALIZATION AND TOXICITY 
 
 
Reproduced in part with permission from Chemical Communications 2013, 49(54), 6048-6050. 
 
Copyright © 2013 
Royal Society of Chemistry 
 
Eladio Mendez and Joong Ho Moon* 
Department of Chemistry & Biochemistry, Florida International University, Miami, Florida 
33199, United States 
 
  
25 
 
2.1. Abstract 
The subcellular localizations and toxicity of conjugated polymer nanoparticles (CPNs) 
are dependent on the chemical structure of the side chain and backbone structures. 
Amine- containing CPNs exhibit high Golgi localization with no toxicity. Incorporation 
of short ethylene oxide and tertiary amine side chains contributes to decreased Golgi 
localization and increased toxicity, respectively. 
2.2. Introduction 
Semiconducting conjugated polymer nanoparticles (CPNs) and conjugated 
polyelectrolytes (CPEs) are emerging fluorescent biomaterials for cellular labelling,1 
sensing,2 therapeutic,3 and delivery4 of biological substances. Conjugated Polymers’ 
(CPs) excellent photophysical properties including high molar absorptivity, quantum 
yield, and energy transfer efficiency make them suitable for the various biological 
applications.5 Well established synthetic methods also allow facile modifications of both 
π-electron conjugated backbones and side chains with various sensing or targeting units. 
By treating non-aqueous soluble CPs under various particle formation conditions, non-
toxic soft nanoparticles have been fabricated and used for cellular labelling and nucleic 
acid delivery.6   
Understanding cellular interactions and entry pathways of CPNs is paramount to 
improving overall labelling and delivery efficiency. Depending on the entry pathways, 
the materials and its payloads (i.e., drugs or genes) will be trafficked into different 
organelles, which will significantly influence the overall efficiency.7 For example, 
carriers entrapped in endosomes or lysosomes trafficked via a certain type of endocytosis 
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will experience recycling of the contents back to the cell surface and degradation 
processes in acidic lysosomes, lowering overall labelling and delivery efficiency.8 
Meanwhile, exogenous materials trafficked by non-destructive organelles such as 
caveosomes to Golgi apparatus (i.e., caveolae-mediated endocytosis) have high 
intracellular retention.9 Delivery via macropinocytosis also can avoid lysosomal 
degradation routes because macropinosomes do not fuse with the lysosomes, and the 
membranes of macropinosomes are highly leaky.10 Therefore, systematic investigation to 
understand and modulate the cellular interaction and pathways will have significant 
impact on designing efficient labelling and delivery vehicles. 
Previously, we demonstrated that CPNs fabricated by treating a CP containing both short 
ethylene oxide (EO) and primary amine (e.g., P1, Figure  1) with organic acids followed 
by dialysis exhibit efficient cellular labelling and delivery of small interfering RNA 
without toxic   effects.4a,b    Mechanistic  studies    further indicate   that   CPNs use both  
 
Figure 2.1. Chemical structures of amine-containing CPs. Poly(p-phenyleneethynylenes) (PPEs) with 
different side chains (P1-P3) and poly(p-phenylenebutadiynylene) (PPB) containing a small amount of 
flexible unit in the backbone (P4) were synthesized and compared for cellular behaviours. 
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energy-dependent and independent entry pathways. Among the energy dependent 
pathways, CPNs enter cancer cells via caveolae-mediated endocytosis as one of entry 
pathways.11 It is not clear why the CPNs use the specific entry pathway; however, the 
positive charges and hydrophobicity of CPNs play important roles for interaction with 
various serum proteins and the cell membranes, which will significantly influence the 
subsequent cellular uptake.12 It is also known that materials having high surface-to-
volume ratios exhibit size, shape, and functional group-dependent cellular interactions 
and subsequent entry.13 
Based on these results and observations, we hypothesized that chemical modifications in 
the side chains of CPs will change the subcellular localizations of CPNs, because the 
modulated surface properties will influence the cellular interactions of CPNs and their 
subsequent entry into cells.  
2.3. Results and Discussion 
To test the hypothesis, we synthesized four CPNs with different side chain (P1-3) and 
backbone structures (P4) (Figure  1). Since the cellular interactions and entry processes 
of nanomaterials are collectively influenced by the physicochemical properties, it is 
important to keep other physicochemical properties constant when a specific parameter is 
tested. Because of the particle formation mechanism (i.e., molecular weight independent 
phase inverse precipitation driven by aqueous insolubility of CPs),14 the shapes and 
hydrodynamic radii of CPNs are relatively constant.15 CPN-2 was designed and 
synthesized to check the EO side chain effects on the toxicity and localization by 
removing the EO unit from the repeating unit of CPN-1. CPN-3 was synthesized to 
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Toxicity and Subcellular Localization 
To test how the side chain structure influences cellular toxicity, CPNs were incubated 
with human cervical carcinoma cells (HeLa) overnight at various concentrations. Zeta 
potentials of CPNs had no direct correlation to the toxicity, but the chemical structure 
(i.e., type and density of amine) of the side chains was related to the cellular toxicity. As 
shown in Figure  2, CPN-3 containing the highest amine density, including tertiary 
amines, exhibited substantial toxicity starting from 10 µM, while no cell viability 
inhibition was observed up to 40 µM from the primary amine containing CPNs, whether 
they contain EO side chains or flexible backbones (i.e., CPN-1, -2, and -4). Compared to 
CPN-2, which contains the same amount of primary amines per repeating unit as CPN-3, 
toxicity of CPN-3 can be attributed to both increased amine density and the high 
buffering capacity of tertiary amines. Membrane disruption properties of synthetic 
carriers  
 
Figure 2.2. Cellular toxicity of amine-containing CPNs measured by cell  
viability inhibition at various concentrations 
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containing tertiary amines have been used to increase payload escape from the 
endosomes or lysosomes; however, these classes of materials often cause toxicity 
issues.17 
Subcellular localization of CPNs was monitored by fluorescent microscopic imaging. 
Overnight treatment of HeLa cells with CPNs (green) were co-stained with pHRhodo 
Dextran (10kDa) (red) and BODIPY-TR C5-ceramide-BSA complex (red) for labelling 
acidic organelles (i.e., endosomes and lysosomes) and Golgi apparatus, respectively 
(Figure  3a and ESI). CPNs were mainly found at the perinuclear regions (punctuated 
green dots) and exhibited overlaps with both pHRhodo and BODIPY. Co-localization 
patterns with the Golgi were clearly distinguishable among CPNs having different side 
chain or backbone structures (Figure  3a), while overlapping patterns with pHRhodo were 
relatively uniform. CPN-2 and CPN-4, which only contain primary amine side chains, 
exhibit high Golgi localizations (Figure  3a), while CPN-1 and CPN-3, which contain 
both EO and amine side chains, exhibit a relatively low Golgi overlaps.  
To obtain quantitative co-localization information, all images were further analysed using 
the Pearson's Correlation Coefficient (PCC) method. The PCC method gauges the level 
of overlap by measuring the pixel-by-pixel covariance in the signals of two images. 
Because the PCC method uses normalized signals by subtracting the mean intensity from 
each pixel's intensity value, PCC is independent of signal levels (probe brightness) and 
signal offset (background).18 PCC values of 0 and 1 correspond to uncorrelated and 
perfectly linear correlated images, respectively. Instead of picking small, subjective 
regions of interest within an image, three independent images of an entire cell were 
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CPN Accumulation and Retention 
The different CPN organelle trafficking is expected to significantly influence the 
polymer’s accumulation intracellular retention within the cell. Because all CPNs 
exhibited entrapment in late endosomes/lysosomes, they will experience recycling back 
to the cell surface and degradation processes in acidic lysosomes. However, those 
polymers exhibiting significant traffic to the Golgi apparatus (i.e. CPN-2 and CPN-4) 
should exhibit increased cellular retention. To measure CPN accumulation, cellular 
uptake was measured using flow cytometry after 2 hours and overnight (18 hours) 
treatment with CPN.  To measure CPN retention within the cell, cellular uptake was 
measured by treating cells with the CPN for 2 hours, exchanging media, and allowing 
HeLa cells to incubate overnight (16 hours). Any remaining fluorescent signal from the 
CPN within the cell was measured. Cellular uptake comparison between CPNs was made 
possible by normalizing the mean fluorescence measurements measured by flow 
cytometer with the CPN quantum yield. It is not expected that CPNs exhibit significant 
QY changes upon cellular internalization.  
For all treatment times tested, CPN-4 and CPN-1 exhibited the highest and lowest 
uptake, respectively (Figure 2.5). After 2 hours of treatment, CPN-2 and CPN-4 
exhibited a 4-fold and 8-fold enhancement to cellular uptake over CPN-1, respectively. 
After overnight treatment, CPN-2 and CPN-4 exhibited a 6-fold and 12-fold 
enhancement to cellular uptake over CPN-1, respectively. Additionally, CPN-1 did not 
show any significant difference in uptake between the 2 hour and overnight treatments. In 
contrast, when comparing 2 hour and overnight treatments, CPN-2 and CPN-4 exhibited  
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that even after overnight incubation CPN-2 and CPN-4 exhibited higher fluorescence 
signal than even CPN-1 after overnight treatment.  
 
2.4. Conclusion  
In conclusion, we demonstrated that CPNs are promising biomaterials with tunable 
physicochemical properties. The side chain and backbone structures of CPNs are closely 
related to toxicity and subcellular localization. Therefore, cellular interaction and cellular 
entry pathways of CPNs can be fine-tuned to improve labelling and delivery efficiency. 
The non-destructive delivery pathway and subcellular location of CPN-2 and CPN-4 
afforded biocompatible materials exhibiting remarkable internalization, accumulation and 
cellular retention. Combining their excellent intrinsic fluorescent natures, tunable 
physicochemical properties and the related biophysical properties, CPNs make excellent 
biomaterials to better understand the structure-function between nanocarrier and delivery 
efficiency. The concept we demonstrated here will lead to the development of novel 
multifunctional materials for labelling, sensing, and delivery. 
2.5.     Outlook   
Since the publication of this work in Macromolecules, a preliminary study of the 
endocytosis pathway of each CPN was performed. Using pharmacological inhibitors, it 
was observed that the main endocytotic pathway for EO and primary amine-containing 
CPN-1 is via CvME, and secondarily via CME. For the primary amine-containing CPN-
2, the reverse result was observed, with a primary entry mechanism using CME and 
secondarily via CvME. Branched amine-containing CPN-3 exhibited MPC as its primary 
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endocytosis pathway, with CvME its secondary mechanism. Finally, the semi-flexible 
backbone-containing CPN-4 exhibited almost exclusive MPC uptake, with very weak 
secondary internalization via CvME uptake.  
Interestingly, CPN-2 and CPN-4, both of the high Golgi co-localizing materials presented 
in this chapter exhibited very different internalization mechanisms. This preliminary 
endocytosis pathway confirmed CPN-2’s CvME, which we hypothesized would be the 
internalization pathway due to the high Golgi uptake. However, CPN-4 exhibtied very 
little CvME uptake, instead showing almost exclusive MPC mechanism. In chapter 4, a 
triphenyl phosphonium-containing CPN is presented exhibiting polymeric cellular 
internalization and degradation into conjugated polymer oligomer endosomal escape. We 
cautiously hypothesize a similar mechanism for CPN-4, whereby the resulting amine-
containing conjugated oligomers are trafficked to the Golgi apparatus.  
Further studies on polymers using CPNs presented here have revealed the unique ability 
for semi-flexible linker containing-CPNs (i.e. CPN-4) to undergo self-assembly 
reorganization into core-shell nanoparticles upon polyanion complexation. This ordered 
aggregation allowed for the fabrication of unique CPNs for glycosaminoglycan 
detection.19 In conclusion, the concept presented here has and will continue to facilitate 
development of novel multifunctional materials for labelling, sensing, and delivery. 
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Experimental Section  
2.6.1. General  
Chemicals, including solvents, were purchased from Fisher Scientific and used as 
received. Deuterated solvents were purchased from Cambridge Isotope Laboratories 
(Cambridge,MA). UV−vis spectra were recorded using a Varian Cary 50 Bio 
spectrophotometer. Fluorescence spectra were obtained using a FluoroLog-3 
Spectrofluorometer (Jobin Yvon/ Horiba). 9,10-diphenylanthracene (QY = 1.0) in 
cyclohexane was used as a fluorescence standard for QY determination. Hydrodynamic 
radii and Zera potentials were determined by the dynamic light scattering technique using 
a Zetasizer nano−ZS (Zen 3600, Malvern Instruments Ltd. , Worcestershire, United 
Kingdom). Disposable capillary cell (DTS1061, Malvern Instruments Ltd., 
Worcestershire, United Kingdom) used for zeta potential measurements. Low volume 
disposable cuvettes (ZEN0040, Malvern Instruments Ltd., Worcestershire, United 
Kingdom) used for DLS analysis. The average molecular weight (Mn) and polydispersity 
index (PDI = Mw/Mn) of the polymers were determined by gel permeation 
chromatography (GPC) against polystyrene standards using a Shimadzu high 
performance liquid chromatography (HPLC) system fitted with PLgel 5 μm MIXED-D 
columns and SPD-20A ultraviolet− visible (UV−vis) detector. Nuclear magnetic 
resonance (NMR) spectra were recorded on a 400 MHz and 600 MHz Avance Bruker 
NMR spectrometer. The 600 MHz NMR spectrometer is equipped with a gradient system 
capable of producing magnetic field pulse gradients in the z-direction of about 50 G cm-1 
and allowing for water preak suppression (δ = 4.8 ppm in D2O). Experiments were 
carried out using a 5 mm BBI probe and the temperature was 298K. The mixing time was 
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300 ms water suppression experiments. Chemical shifts were reported in parts per million 
(ppm) for 1H-NMR on the δ scale based on the middle peak (δ = 2.50 ppm) of the 
dimethyl sulfoxide (DMSO)-d6 solvent as an internal standard, or 4.8ppm for deuterium 
hydroxide (D2O) experiments. Dialysis and solvent exchange of CPNs were conducted 
using an Ultrafiltration Stirred Cell (Millipore, Billerica, MA, USA) with membrane 
filters [Ultracel ultrafiltration disc, molecular weight cutoﬀ (MWCO): 30 kDa]. Tables 
and graphs were plotted using Origin 8 software (OriginLab, Northampton, MA, USA).  
2.6.2. Monomer Synthesis 
Monomer 1 (M1) was synthesized according to Scheme 1. tert-butyl 2,2'-
azanediylbis(ethane-2,1-diyl)dicarbamate 1 and 2-(2-(2-chloroethoxy)ethoxy)ethyl 4-
methylbenzenesulfonate 2 were synthesized according to literature procedures.20,21 
Condensation of 2 and 2,5-diiodohydroquinone in the presence of K2CO3 in 2-butanone 
resulted in 3. Reaction of 1 with 3 using K2CO3 base in acetonitrile resulted in the 
formation of M1. 3 and M1 were fully characterized by NMR and mass spectroscopy.  
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tert-butyl 2,2',2'',2'''-[2,2'-(2,2'-[2,2'-(2,5-diiodo-1,4-phenylene)bis(oxy)bis(ethane-2,1-
diyl)]-bis-(oxy)bis(ethane-2,1-diyl)]bis(oxy)bis(ethane-2,1-diyl)]bis(azanetriyl-
)tetrakis(ethane-2,1-diyl)-tetracarbamate (M1): A suspension of compound 1 (1.51 
mmol; 1 g), compound 3 (3.17 mmol; 0.96 g) and potassium carbonate (3.171 mmol; 
0.28 g) in 40 mL of MeCN was refluxed for 3 days. The mixture was concentrated in 
vacuo and diluted with dichloromethane 30 mL. The solution was washed with brine (10 
mL x3), dried (Na2SO4), and evaporated in vacuo. The crude product was purified by 
column chromatography (silica gel, ethyl acetate/hexane (1:1, v/v). Yield: 0.4g (44%) 
Rf=0.47 (3:1 ethyl acetate/hexane). 1H-NMR(400 MHz) : δ = 7.25 (s, 1H, NH-COO), 
7.23 (s, 1H, Ar-H), 4.10 (t, 2H, Ar-O-CH2, J = 6) , 3.90 (t, 2H, CH2O, J = 6), 3.82 (t, 2H, 
OCH2, J = 6), 3.68 (t, 2H, OCH2, J = 6), 3.52(br,2H, OCH2), 3.14 (br, 4H, CH2 nHBoc, J 
= 6), 2.68 (br,2H,CH2 nH), 2.62 (br,4H, NHCH2) 1.45 (s, 18H, OC(CH3)3); 13CNMR(400 
MHz): δ = 156.9, 144.3, 121.1, 83.7, 77.2, 70.6, 70.4, 70.3, 70.1, 59.1, 54.2, 53.7, 51.2, 
50.7, 38.9, 27.3. HRMS (FTICR): Calcd. for C46H82I2 n6O14 [M+H]+: 1197.4051; found 
[M+H]+: 1197.4032.   
Monomer 2 (M2) was synthesized according to Scheme 2. tert-butyl 2-(2-hydroxy-
ethoxy)ethylcarbamate 4, 2-(2-(tert-butoxycarbonylamino)ethoxy)ethyl 4-
methylbenzene-sulfonate 5, and tert-butyl 2,2'-[2,2'-(2,5-diiodo-1,4-
phenylene)bis(oxy)bis(ethane-2,1-diyl)]bis-(oxy)bis(ethane-2,1-diyl)dicarbamate 6 were 
synthesized according to literature procedures.22-24 Coupling of 6 with 
trimethylsilylacetylene using Sonogashira coupling yielded compound 7, which was 
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ethyl acetate/ hexane (4:1, v/v). Yield : 0.94g ( 71 %). 1H-NMR(400 MHz) : δ = 7.23 (s, 
1H, Ar-H), 5.0 (s, 1H, CH2-NH), 4.10 (t, 2H, Ar-OCH2, J = 6), 3.81 (t, 2H, OCH2, J = 6), 
3.83 (t, 2H, OCH2, J = 6), 3.65 (s, 1H, ArCCH), 3.36 (q, 2H, CH2 nH, J = 6), 1.43 (s, 10H, 
OC(CH3)3), 0.05 (s, 9H, TMS). 13C-NMR(400 MHz) : δ = 171.1, 156.0, 154.0, 118.1, 
114.5, 100.8, 79.1, 77.5, 71.9, 70.6, 69.6, 68.0, 60.4, 53.5, 41.3, 28.4, 21.0, 19.2, 14.2. 
HRMS (FTICR): Calcd. for C34H56 n2O8Si2 [M+H]+: 677.3648; found [M+H]+: 677.3644.   
 
tert-butyl 2,2'-[2,2'-(2,5-diethynyl-1,4-phenylene)bis(oxy)bis(ethane-2,1-diyl)]bis(oxy)-
bis(-ethane-2,1-diyl)dicarbamate (M2): A 20 mL vial was charged with compound 8 
(1.42 mmol, 0.400 g), Potassium carbonate (0.70 mmol, 0.100 g) 15 mL of MeOH and 
left to stir overnight at room temperature. The resulting mixture was gravity filtered, the 
solvent was evaporated and the reaction mixture was purified by column chromatography 
(silica gel, ethyl acetate). Yield : 0.34g (90 %). 1H-NMR(400 MHz) : δ = 7.00 (s, 1H, Ar-
H), 5.0 (s, 1H, CH2-NH), 4.15 (t, 2H, Ar-OCH2, J = 6), 3.81 (t, 2H, OCH2, J = 6), 3.65 (t, 
2H, OCH2, J = 6), 3.39 (s, 1H, ArCCH), 3.36 (q, 2H, CH2 nH, J = 6), 1.56 (s, 10H, 
OC(CH3)3); 13C-NMR(400 MHz) : δ = 156.7, 154.1, 118.3, 113.7, 83.0, 79.5, 71.9, 70.6, 
69.3, 69.25, 40.7, 28.4. HRMS (FTICR): Calcd. for C28H40 n2O8 [M+H]+: 533.2857; 
found [M+H]+: 533.2849.   
 
Monomer 3 (M3) was synthesized according to Scheme 3. 2-(2-methoxyethoxy)ethyl 4-
methyl-benzenesulfonate 8, 1,4-diiodo-2,5-bis(2-(2-methoxyethoxy)ethoxy)benzene 9, 
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dimethylformamide (DMF) (4 mL) and freshly distilled trimethylamine (1 mL) was 
degassed, and 1 mL of the mixed solution was transferred to the Schlenk flask using a 
cannular needle. The reaction was heated at 70 °C for14 h. The solution was then cooled 
to room temperature and transferred dropwise to cold ethyl ether, resulting in 
precipitation. After centrifugation (2 min, 4000 rpm), the supernatant was decanted, and 
the precipitate was redissolved in DMF (1 mL) for further purification. See Scheme 4.  
2.6.3.2. CPN Formation. Boc-deprotection of the polymer was carried out by mixing a 
solution of polymer in DMSO-d6 with acetic acid (2 mL) and trifluoroacetic acid (1 mL) 
and allowed to stir at room temperature for 5 days. The mixture was then added to acetic 
acid (20 mL), allowed to stir overnight, and centrifuged, and supernatant was added 
dropwise (2 drops/s) to 500 mL water (18 Ω) while stirring. Using a solvent-resistant stir 
cell fitted with a 30 kDa-MWCO membrane, the solution was concentrated to 
approximately 10 mL, and dialyzed against 1 L of water. The resulting solution was 
further dialyzed in a 10 KDa membrane for 3 days. The solution was subsequently 
filtered through a Teflon (PTFE) syringe filter (0.45 μm) and used for further analysis. 
Deprotection was confirmed with 1H-NMR. See Scheme 4.  
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Figure 2.9. ZP for polymer CPN-1 
 
 P2. Using the general procedure described above, the polymerization of 6 (30 mg, 0.056 
mmol) and monomer M2 (41 mg, 0.056 mmol) in the presence of Pd[(PPh3)2Cl2] (4 mg, 
0.0056 mmol) and CuI (0.3 mg, 0.0028 mmol) yielded PPE polymer P2 ( 44 mg, 73%). 
Resulting mixture was purified by precipitation in cold ethyl ether (x3). An aliquot was 
redissolved in THF and molecular weight obtained and photophycal properties 
characterized. The rest of the material was dissolved in DMSO-d6 and characterized 
using 1H-NMR. CPN formation was then carried out as described in general procedure to 
yield CPN-2 
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Figure 2.13. ZP for polymer CPN-2  
 
P3. Using the general procedure described above, the polymerization of monomer 4 (65 
mg, 0.054 mmol) and monomer 13 (32 mg, 0.054 mmol) in the presence of 
Pd[(PPh3)2Cl2] (8 mg, 0.0054 mmol) and CuI (0.4 mg, 0.0022 mmol) yielded PPE 
polymer P3 ( 45 mg, 61%). Resulting mixture was purified by precipitation in cold ether 
(x3). An aliquot was redissolved in THF and molecular weight obtained and photophycal 
properties characterized. The rest of the material was dissolved in DMSO-d6 and 
characterized using 1H-NMR. CPN formation was then carried out as described in 
general procedure to yield CPN-3.  
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Figure 2.17. ZP for polymer CPN-3 
 
Polymer P4. Polymer synthesis, deprotection, CPN fabrication, and characterization is 
described elsewhere.26  
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Figure 2.18. DLS for polymer CPN-4 
 
 
 
Figure 2.19. ZP for polymer CPN-4 
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2.6.3.3. Polymer Deprotection 
Confirmed using 1H-NMR data by looking at characteristic Boc proton peak (1.36ppm) 
and ~1700 cm-1 infrared band for the carbonate (C=O) group. IR samples were prepared 
by lyophilization to prepare neat sample. IR scans from 4000 to 700 cm-1 are presented 
below, depicting absence of boc-carbonate group and confirming deprotection. 
2.6.3.4. Gel Permeation Chromatography 
Samples dissolved in THF were filtered through a Teflon (PTFE) syringe filter (0.25 μm) 
three times. The average molecular weight (Mn) and polydispersity index (PDI = Mw/Mn) 
of the polymers were determined by gel permeation chromatography (GPC) against 
polystyrene standards using a Shimadzu high performance liquid chromatography 
(HPLC) system fitted with PLgel 5 μm MIXED-D columns and SPD-20A ultraviolet− 
visible (UV−Vis) detector. 
2.6.3.5. Dyniamic Light Scattering (DLS) 
Hydrodynamic radii and Zera potentials (ZP) were determined by dynamic light 
scattering technique using a Zetasizer nano−ZS (Zen 3600, Malvern Instruments Ltd.). 
Three polymer aliquots of 500µM CPN were independently prepared by filtering through 
a Teflon (PTFE) syringe filter (0.45 μm). DLS samples loaded in a low volume (1.5 mL) 
disposable cuvette, and Zeta potential samples into disposable capillary cell. Averages 
and standard deviations reported in the main text. Figures S7-14, show representative 
reports for polymer CPN-1, -2, -3 and -4.  
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2.6.4. Cell Culture 
2.6.4.1. General 
 HeLa cells (human cervical cancer, purchased from ATCC), seeded into a 100 x 20 mm 
style sterile tissue culture dish (#353003 BD Falcon, Durham, NC, USA), cultured in 
minimum essential medium (MEM)/Earle’s balanced salt solution (EBSS) (400 μL, 
HyClone, SH30024) medium containing 10% fetal bovine serum (FBS) and 100 U/m 
penicillin for 24 h under 5% CO2 at 37 °C, and subcultured every 48 hours. pHRhodo 
Dextran 10kDa (#P10361 Molecular probes, Life technologies, New York, USA) and 
BODIPY-TR C5 -ceramide-BSA complex (#B34400 Molecular probes, Life 
technologies, New York, USA) were used for endosome and Golgi apparatus staining, 
respectively.  
2.6.4.2. Microscopic Imaging 
10,000 HeLa cells were seeded into a glass-bottomed eight-well chamber slide (Lab-Tek 
Thermo Scientific) and cultured in a minimum essential medium (MEM)/Earle’s 
balanced salt solution (EBSS) (400 μL) medium containing 10% fetal bovine serum 
(FBS) and 100 U/m penicillin for 24 h under 5% CO2 at 37 °C. 80 μL of 20 μM CPNs in 
water was added to the culture medium directly, and the cells were further cultured 
overnight (final CPN concentration: 4 μM). For endosome staining, pHRhodo Dextran 
10kDa (5µM) was incubated for 30 min at 37oC. For Golgi apparatus staining, BODIPY-
TR C5 -ceramide-BSA complex (final 10 μM) was incubated for 30 min at 4 °C. After 
washing with fresh medium, the cells were further incubated for 30 min at 37 °C. A 1 μL 
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aliquot of Hoechst (5 μg/mL) was added to the culture medium and incubated with the 
cells for 10 min at 37 °C, and washed two times with phosphate buﬀered saline (PBS). 
The cells were fixed with 4% paraformaldehyde for 10 min. Fluorescent images of the 
cells were obtained using a DeltaVision Elite Microscope System (Applied Precision, 
Issaquah, Washington, USA) equipped with bandpass filters such as blue (410−460 nm, 
Hoechst), green (500−550 nm, CPNs), and red (595-635 nm, Golgi and endosome). Top 
and bottom of the chosen cells was identified, and a Z-stack plot was imaged for each 
channel.  
2.6.4.3. Colocalization study 
 Z-stack microscope images of each sample was obtained as described above. 
Colocalization analysis was conducted for three independent cells per polymer and per 
organelle (Golgi apparatus and endosome). Colocalization analysis was conducted using 
the microscope software (Softworx 5.0 application, Applied Precision, Issaquah, 
Washington, USA). Region of interest (ROI) was selected to contain all of the cell. 
Pearsons Correlation Coefficient (PCC) was used to determine colocalization. Negative 
control of colocalization was performed by analysis of blue and green channels staining 
the nucleus and CPN, respectively. Three independent images of an entire cell were 
selected and analysed to increase the analysis objectivity. A representative example is 
shown in figure 2.20.  
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°C. CPNs with various concentrations (5 to 40 μM) were added and incubated overnight. 
To measure toxicity, 10 μL of WST-1 [2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium] (Cayman Chemical, Ann Arbor, MI, USA) solution was 
added into each well, and the plate was further incubated for 4 h at 37 °C. Cell viability 
was compared by measuring absorbance values at 450 nm using a microplate well reader 
(Synergy 2, BioTek, Winooski, VT, USA). Relative cell viability as a function of CPN 
concentration was obtained by subtracting absorbance values of each sample well with 
control CPN absorbance at 450 nm.  
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CHAPTER III 
 
COMPLEXATION-DEPENDENT SUBCELLULAR LOCALIZATION  
AND UPTAKE 
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3.1. Abstract 
The cellular uptake and subcellular localizations of conjugated polymer nanoparticles 
(CPNs) is significantly affected upon complexation with polysaccharides. Incorporation 
of short ethylene oxide onto amine-containing CPNs afford polyplexes with reduced late 
endosome/lysosome localization and enhanced cellular uptake. CPNs with only amine 
side-chains, regardless of backbone structure, did not exhibit enhanced cellular uptake.  
3.2. Introduction 
Semiconducting conjugated polymer nanoparticles (CPNs) have attracted much attention  
for cellular labelling,1 sensing,2 and delivery of therapeutics. 4 Upon treating non-aqueous 
soluble conjugated polymers (CPs) under various particle formation conditions, they can 
form non-toxic soft nanoparticles for cellular labelling and nucleic acid delivery.5  
Previously, we fabricated various cationic CPNs by treating a non-aqueous soluble, 
primary amine-containing poly(p-phenyleneethynylene) (PPE) and flexible-linker 
containing poly(p-phenylenebutadiynylene) (PE-d-PPB) with organic acids followed by 
dialysis.6 The CPN’s subcellular localizations and toxicity were dependent on the 
chemical structure of the side chain and backbone structures. Amine-containing PPEs and 
PE-d-PPBs exhibited high Golgi localization with no toxicity. Upon incorporation of 
short ethylene oxide chains Golgi localization significantly decreased. Recently, we 
demonstrated that upon complexation with hyaluronic acid (HA), CPNs form fluorescent 
core-shell nanoparticles exhibiting photophysical, size, and morphological changes.7 
These changes were enhanced when the CPN contained a semi-flexible linker. The 
resulting polymer-polysaccharide complex (polyplex) exhibited improved cancer cell 
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specificity towards human cervical carcinoma (HeLa) cells. Several nanocarrier platforms 
have reported similar formulations with naturally-derived polymers.8  Upon preparation, 
these formulations these formulations have afforded nanocarriers with increased stability, 
improved pharmacokinetics, improved cancer-specificity and lower toxicity.  
While active targeting by CPNs remains highly desirable, it becomes clear that to 
improve the drug efficacy the nanocarrier should not only facilitate successful delivery 
into specific cell types or tissues, but direct the drug to its appropriate intracellular 
destination. Because most drugs require delivery specific organelles, the increased 
cancer-cell specificity and decreased carrier toxicity will not improve delivery efficiency 
if the drugs are not delivered to the proper organelle.  Therefore, understanding how 
subcellular localization and uptake are affected upon polysaccharide complexation is 
paramount to improving overall labelling and delivery efficiency.  
Work towards understanding how CMC or HA complexation affects nanoparticle uptake 
efficiency and subcellular fate has been limited. Hyaluronic acid has been reported to 
display molecular-weight dependent endocytosis pathways.9 Receptor-mediated 
endocytosis and macropinocytosis of bulk phase HA have been reported for low (104 
kDa) and high molecular (106 kDa) weight HA, respectively. Although mechanistic 
studies of CMC uptake mechanisms remain limited, various compounds incorporating 
CMC or using CMC hydrogels report late endosome, and lysosomal co-localization and 
improved HeLa cell uptake.10 Previously, we reported that core-CP shell-HA 
nanoparticles can be obtained when semi-flexible CPs were treated with polyanionic HA, 
while non-flexible CPs produce random complexes upon HA treatment. 11 Therefore, we 
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side chain effects from non-EO containing CPN-1 and the resulting complexation and 
cell uptake behavior. CPN-3 was designed to test the effect the biodegradable-linker has 
on the complexation and uptake behavior compared to CPN-2.  
Subcellular localization of CPNs was monitored by fluorescent microscopic imaging. 
Overnight treatment of HeLa cells with CPNs (green) were co-stained with pHRhodo 
Dextran (10kDa) (red) for labelling acidic organelles (i.e., endosomes and lysosomes) 
after overnight CPN/polyplex treatment. The Pearson's Correlation Coefficient (PCC) 
was used to examine co-localization evaluation, with scores of 0 and 1 correspond to un-
correlated and perfectly linearly correlated colors, respectively. Mean PCC scores from 
three independent images of an entire cell were selected and analyzed to examine 
analysis variance. Changes in cellular uptake were measured using flow cytometry for 
polymers by themselves and after complexation with CMC or HA.   
3.3 Results and Discussion 
Subcellular Localization 
To test how the CPN’s subcellular localization is influenced upon CMC or HA 
complexation, the CPN polyplexes were incubated with human cervical carcinoma cells 
(HeLa) overnight. As shown in Figure  3.2, CPN-2 exhibited no significant change to late 
endosome/lysosome localization upon complexation with HA or CMC. CPN-1 
polyplexes exhibited significant decreases in late endosome/lysosome localization, 
suggesting a decrease in adsorptive endocytosis. If CPN-1’s high endosomal/lysosomal 
co-localization is the result of the polymer’s non-specific interaction with generic 
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late endosome/lysosome colocalization because of core-CP shell-CMC/HA morphology 
that is facilitated by the semi-flexible nature of the material. Indeed, this was indeed 
observed for both CMC and HA polyplexes.  
CPN Polyplex cellular uptake 
To measure the CPN-polysaccharide polyplex accumulation was measured using flow 
cytometry. Briefly, cellular uptake was measured after 2 hours and overnight (18 hours) 
treatment.  To measure the polyplex retention/clearance, cellular uptake was measured by 
treating cells with the CPN for 2 hours, exchanging media, and allowing HeLa cells to 
incubate overnight (16 hours). Any remaining CPN signal within the cell can be 
measured to compare relative retention between CPNs. Cellular uptake comparison 
between these polyplexes was made possible by normalizing the mean fluorescence 
measurements obtained from the flow cytometer.  
The cellular uptake by the non-flexible CPNs, and the resulting polyplex upon HA and 
CMC complexation are summarized in figure 3.3. The resulting polyplex of CMC/HA 
with CPN-1 resulted in a 2-fold enhancement into HeLa cells for all treatment times 
tested. There was no significant difference between the uptake facilitated upon CMC or 
HA complexation. The significant increase in uptake is interesting, when coupled with 
the fact that late endosome/lysosome localization significantly decreased for the CPN-1 
polyplexes. The combined results provide further evidence supporting the subcellular 
localization changes exhibited by CPN-1 resulting from decreased non-specific 
interaction with generic complementary binding sites, like negatively charged heparin  
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3.4. Conclusion 
The significant decrease in uptake upon complexation with HA and CMC, coupled with 
the subcellular changes that resulted in increased late endosome/lysosome localization 
after overnight treatment, do not support our initial hypothesizes that CPN-3 would 
exhibit the most significant cellular uptake enhancement. We expected improved uptake 
due to the formation of core-CP shell-CMC/HA morphology that is facilitated by the 
semi-flexible nature of the material.  If the uptake is significantly influenced by the 
complexing polysaccharide, then we expect the polyplex to exhibit improved 
internalization via macropinocytosis. This phenomenon could be occurring for both 
CPN-2 and CPN-3 polyplexes, however, the increased amine-density in both CPNs 
might make diffusion out of the macropinocytotic vesicle difficult. There is further 
evidence supporting this hypothesis, as CPN-1, containing half the amine density of 
CPN-2 and CPN-3, indeed exhibits the uptake enhancement and decreased endosome 
localization we expected from CPN-3. In conclusion the cellular uptake and subcellular 
localizations of CPNs were significantly affected upon complexation with 
polysaccharides. Incorporation of short ethylene oxide onto amine-containing CPNs 
afford polyplexes with reduced late endosome/lysosome localization and enhanced 
cellular uptake. CPNs with only amine side-chains, regardless of backbone structure, did 
not exhibit enhanced cellular uptake. A detailed study in the endocytosis mechanisms for 
the uptake of these polyplexes could shed light into this interesting phenomenon.  
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3.5.     Outlook   
Since the writing of this chapter, a preliminary study of the endocytosis pathway of each 
CPN-polysaccharide polyplex was performed. The endocytosis pathways for CPN-1, 
CPN-2 were previously determined to be CvME/CME and CME/CvME, respectively 
(see Chapter 2). CPN-3 was determined to be MPC. Upon complexation with HA, all 
resulting HA-polyplexes exhibited MPC and CvME as their main and secondary 
endocytosis pathways, respectively. This observed change in endocytosis pathway 
occurred regardless of the nature of the polymer used. These results further support our 
hypothesis. We had observed improved uptake due to the formation of core-CP shell-
CMC/HA morphology that is facilitated by the semi-flexible nature of the material.  If the 
uptake is significantly influenced by the complexing polysaccharide, then we expected 
the polyplex to exhibit improved internalization via macropinocytosis. We did in fact 
observe this phenomenon upon HA complexation. The effects on endocytosis pathway 
were upon CMC complexation were not as significant, however. The resulting increase in 
hydrodynamic radius of the CMC-polyplex could cause the observed changes, and 
remains an interesting avenue for future work.    
Further studies on polymers using semi-flexible CPNs here have revealed that the nature 
of the conjugated backbone, and the amount of flexible linker play a crucial role in the 
controlled aggregation of the resulting polyplex. In conclusion, the understanding the role 
that backbone and the semi-flexible linker play in the controlled aggregation, and the 
resulting biophysical properties, will continue to facilitate development of novel 
multifunctional materials for labelling, sensing, and delivery. 
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3.6. Experimental Section 
3.6.1. General  
Chemicals, including solvents, were purchased from Fisher Scientific and used as 
received. Deuterated solvents were purchased from Cambridge Isotope Laboratories 
(Cambridge, MA). UV−vis spectra were recorded using a Varian Cary 50 Bio 
spectrophotometer. Fluorescence spectra were obtained using a FluoroLog-3 
Spectrofluorometer (Jobin Yvon/ Horiba). 9,10-diphenylanthracene (QY = 1.0) in 
cyclohexane was used as a fluorescence standard for QY determination. The average 
molecular weight (Mn) and polydispersity index (PDI = Mw/Mn) of the polymers were 
determined by gel permeation chromatography (GPC) against polystyrene standards 
using a Shimadzu high performance liquid chromatography (HPLC) system fitted with 
PLgel 5 μm MIXED-D columns and SPD-20A ultraviolet− visible (UV−vis) detector. 
Nuclear magnetic resonance (NMR) spectra were recorded on a 400 MHz and 600 MHz 
Avance Bruker NMR spectrometer. The 600 MHz NMR spectrometer is equipped with a 
gradient system capable of producing magnetic field pulse gradients in the z-direction of 
about 50 G cm-1 and allowing for water peak suppression (δ = 4.8 ppm in D2O). 
Experiments were carried out using a 5 mm BBI probe and the temperature was 298K. 
The mixing time was 300 ms water suppression experiments. Chemical shifts were 
reported in parts per million (ppm) for 1H-NMR on the δ scale based on the middle peak 
(δ = 2.50 ppm) of the dimethyl sulfoxide (DMSO)-d6 solvent as an internal standard, or 
4.8ppm for deuterium hydroxide (D2O) experiments. Dialysis and solvent exchange of 
CPNs were conducted using an Ultrafiltration Stirred Cell (Millipore, Billerica, MA, 
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USA) with membrane filters [Ultracel ultrafiltration disc, molecular weight cutoﬀ 
(MWCO): 30 kDa]. Tables and graphs were plotted using Origin 8 software (OriginLab, 
Northampton, MA, USA).  
 
3.6.2 Polymer Synthesis and Characterization  
P3. A Schlenk flask was charged with of monomer 9 (32 mg, 0.044 mmol) and monomer 
13 (20 mg, 0.044 mmol) in the presence of Pd[(PPh3)2Cl2] (3 mg, 0.0044 mmol) and CuI 
(0.2 mg, 0.0022 mmol). The Schlenk flask was evacuated and filled with N2 three times. 
A solution of anhydrous dimethylformamide (DMF) (4 mL) and freshly distilled 
trimethylamine (1 mL) was degassed, and 1 mL of the mixed solution was transferred to 
the Schlenk flask using a cannula needle. The reaction was heated at 70 °C for14 h. The 
solution was then cooled to room temperature and transferred drop wise to cold ethyl 
ether, resulting in precipitation. After centrifugation (2 min, 4000 rpm), the supernatant 
was decanted, and the precipitate was dissolved in DMF (1 mL) to yield P3.  
Molecular weight of boc-protected polymer was obtained and characterized. Resulting 
mixture was purified by precipitation in cold ethyl ether (x3). An aliquot was dissolved in 
THF and molecular weight obtained and photophysical properties characterized. The rest 
of the material was dissolved in DMSO-d6 and characterized using 1H-NMR. CPN 
formation was then carried out as described in general procedure to yield CPN-3.  
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P3: GPC: Mw =24.43 kDa; Mn= 16.4 kDa; PDI = 1.49. UV λmax = 427 nm; fluo λmax(400 
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.35 (br, 1H, Ar-H), 6.87 
(br, 0.5H, NHCOO), 4.08 (br, 2H, Ar-OCH2), 3.91 (br, 2H CH2O), 3.82 (br, 2H, OCH2), 
3.58 (br, 2H, CH2O), 3.48 (br, 2H, OCH2), 3.34 (br, 2H, CH2O), 3.27 (br, 2H, OCH2), 
2.72 (br, 3H, OCH3), 1.47 (s, 8H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w), 
2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m), 
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m). 
CPN-3: UV λmax = 433 nm; fluo λmax(400 nm ex) =496 nm; QY = 3% in water. 1H-
NMR(600 MHz) : δ = 7.36 (br, 1H, Ar-H), 4.3-3.0 (br, 23H, -OCH2-CH2- chains), 1.30 
(s, 0.21H). FT-IR (Neat): ν = 3374 (br), 2982 (w), 2935 (m), 2875 (s), 1674 (br), 1610 
(w), 1500 (m), 1461 (w), 1423 (w), 1390 (w), 1360 (m), 1279 (w), 1250 (w), 1213 (br), 
1104 (br), 1059 (br), 1035 (m). 
 
3.6.2.1 CPN Formation 
Boc-deprotection of the polymer was carried out by mixing a solution of polymer in 
DMSO-d6 with acetic acid (2 mL) and trifluoroacetic acid (1 mL) and allowed to stir at 
room temperature for 5 days. The mixture was then added to acetic acid (20 mL), allowed 
to stir overnight, and centrifuged, and supernatant was added drop wise (2 drops/s) to 500 
mL water (18 Ω) while stirring. Using a solvent-resistant stir cell fitted with a 30 kDa-
MWCO membrane, the solution was concentrated to approximately 10 mL, and dialyzed 
against 1 L of water. The resulting solution was further dialyzed in a 10 KDa membrane 
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for 3 days. The solution was subsequently filtered through a Teflon (PTFE) syringe filter 
(0.45 μm) and used for further analysis. Deprotection was confirmed with 1H-NMR.  
 
3.6.2.2.Polymer Deprotection 
Confirmed using 1H-NMR data by looking at characteristic Boc proton peak (1.36ppm) 
and ~1700 cm-1 infrared band for the carbonate (C=O) group. IR samples were prepared 
by lyophilization to prepare neat sample. IR scans from 4000 to 700 cm-1 are presented 
below, depicting absence of boc-carbonate group and confirming deprotection. 
 
3.6.2.3. Gel Permeation Chromatography 
Samples dissolved in THF were filtered through a Teflon (PTFE) syringe filter (0.25 μm) 
three times. The average molecular weight (Mn) and polydispersity index (PDI = Mw/Mn) 
of the polymers were determined by gel permeation chromatography (GPC) against 
polystyrene standards using a Shimadzu high performance liquid chromatography 
(HPLC) system fitted with PLgel 5 μm MIXED-D columns and SPD-20A ultraviolet− 
visible (UV−Vis) detector. 
3.6.3. Cell Culture 
3.6.3.1. General 
Human cervical cancer (HeLa) cells (purchased from ATCC), seeded into a 100 x 20 mm 
style sterile tissue culture dish (#353003 BD Falcon, Durham, NC, USA), cultured in 
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minimum essential medium (MEM)/Earle’s balanced salt solution (EBSS) (400 μL, 
HyClone, SH30024) medium containing 10% fetal bovine serum (FBS) and 100 U/m 
penicillin for 24 h under 5% CO2 at 37 °C, and subcultured every 48 hours. pHRhodo 
Dextran 10kDa (#P10361 Molecular probes, Life technologies, New York, USA) and 
BODIPY-TR C5 -ceramide-BSA complex (#B34400 Molecular probes, Life 
technologies, New York, USA) were used for endosome and Golgi apparatus staining, 
respectively.  
3.6.3.2. Microscopic Imaging.  
Approximately 10,000 HeLa cells were seeded into a glass-bottomed eight-well chamber 
slide (Lab-Tek Thermo Scientific) and cultured in a minimum essential medium 
(MEM)/Earle’s balanced salt solution (EBSS) (400 μL) medium containing 10% fetal 
bovine serum (FBS) and 100 U/m penicillin for 24 h under 5% CO2 at 37 °C. 80 μL of 20 
μM CPNs in water was added to the culture medium directly, and the cells were further 
cultured overnight (final CPN concentration: 4 μM). For endosome staining, pHRhodo 
Dextran 10kDa (5µM) was incubated for 30 min at 37oC. After washing with fresh 
medium, the cells were further incubated for 30 min at 37 °C. A 1 μL aliquot of Hoechst 
(5 μg/mL) was added to the culture medium and incubated with the cells for 10 min at 37 
°C, and washed two times with phosphate buﬀered saline (PBS). The cells were fixed 
with 4% paraformaldehyde for 10 min. Fluorescent images of the cells were obtained 
using a DeltaVision Elite Microscope System (Applied Precision, Issaquah, Washington, 
USA) equipped with bandpass filters such as blue (410−460 nm, Hoechst), green 
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(500−550 nm, CPNs), and red (595-635 nm, Golgi and endosome). Top and bottom of 
the chosen cells was identified, and a Z-stack plot was imaged for each channel.  
3.6.3.3. Colocalization study 
Z-stack microscope images of each sample was obtained as described above. 
Colocalization analysis was conducted for three independent cells per polymer and per 
organelle (Golgi apparatus and endosome). Colocalization analysis was conducted using 
the microscope software (Softworx 5.0 application, Applied Precision, Issaquah, 
Washington, USA). Region of interest (ROI) was selected to contain the entire cell. 
Pearson’s Correlation Coefficient (PCC) was used to determine colocalization. Negative 
control of colocalization was performed by analysis of blue and green channels staining 
the nucleus and CPN, respectively. Three independent images of an entire cell were 
selected and analyzed to increase the analysis objectivity. Experimental colocalization 
PCC values were obtained using the green and red channels staining the CPN and the 
target organelle (endosome). One-way ANOVA followed by Tukey means separation 
method was conducted for PCC colocalization values between samples of same organelle 
using Origin 8 software.  
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CHAPTER IV 
 
 
POLYMER BACKBONE DEGRADATION-DEPENDENT  
SUBCELLULAR LOCALIZATION 
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4.1. Abstract 
Quantitative mitochondria labeling was achieved by endocytosis of biodegradable 
conjugated polymer nanoparticle (CPN) followed by the polymer backbone degradation. 
The degraded conjugated oligomers (COs) were efficiently trafficked to the target 
organelle, while non-degradable CPNs remain mainly in endosomes. The presented 
strategy of highly specific intracellular labeling of target organelle will contribute to 
increase accuracy of biological imaging and sensing.   
4.2. Introduction 
Mitochondrial dysfunction is a key component in various human diseases such as 
cancer1, obesity2, diabetes3 and neurodegenerative diseases ranging from Leber’s 
hereditary optic neuropathy4 to Alzheimer's disease5. Because the mitochondrion plays a 
key role in cell death pathways, targeted drug delivery to this organelle could play a 
crucial role for future cancer treatments.6 However, the efficient delivery of therapeutics 
into this key organelle has been limited by the highly regulated process required to 
achieve mitochondrial internalization.  
Successful drug delivery requires permeation through the lipophilic cell membrane, 
mitochondrial trafficking, and penetration of the mitochondrial membrane, which results 
in a high exclusivity towards a wide variety of molecules. Incorporation of lipophilic 
moieties such as triphenylphosphonium (TPP), which contain a delocalized positive 
charge, has been reported to facilitate cellular and mitochondrial membrane permeation.7 
While direct modification of drugs with TPP, or targeting moieties like it8, has facilitated 
internalization into the mitochondria, they are limited to small molecular weight payloads 
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and suffer from non-specific cellular adsorption.9 Additionally, the intrinsic diffusion 
mechanism requires relatively high probe concentrations, which often lead to non-
specific uptake and toxicity issues.  
Polymeric delivery vehicles overcome many of the limitations of direct drug modification 
and offer a platform that that can be modified for the intracellular delivery of cargos of 
varying charge, size, and molecular weight. Upon appropriate fabrications and surface 
modifications, polymer nanoparticles can circulate longer in the blood stream and target 
the disease tissues using both passive (i.e., the enhanced permeation and retention effect) 
and active (i.e., interaction of ligands specific to the cell surface receptors) targeting 
strategies. 
Mitochondrial localization of nanocarriers via incorporation of targeting ligands has seen 
limited success. For example, mitochondrial localization was observed by incorporation 
of TPP onto N-(2-Hydroxypropyl)methacrylamide (HPMA) only in copolymers with an 
average molecular weight below 5 kDa. Higher molecular HPMA copolymers did not 
show any mitochondrial localization, even after polymer microinjection into the cytosol. 
Emerging technologies such as dequalinium, which can form liposome-like aggregates, 
have been reported to exhibit plasmid DNA (pDNA) encapsulation, cellular 
internalization, and pDNA delivery to the mitochondria. Similar success has been 
reported with fusogenic peptides. However, these materials do not exhibit improved 
pharmacokinetics, passive or active targeting towards cancer cells.  
Here we present a strategy to combine advantages of both small molecules (i.e., high 
targeting efficiency) and large polymeric materials (i.e., better cellular entry and in vivo 
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properties) to achieve quantitative intracellular organelle labeling. Using the 
biodegradability of conjugated polymer nanoparticles (CPNs), almost quantitative 
mitochondria labeling was achieved. Upon endocytosis, CPNs were de-assembled and 
degraded to low molecular weight, fluorescent mitochondria probes that were efficiently 
trafficked to mitochondria. The results support that biodegradable CPNs are promising 
labeling and therapeutic delivery materials to mitochondria. 
CPNs are fluorescent biomaterials fabricated by self-assembly of non-aqueous solution 
conjugated polymers (CPs) in an aqueous solution. Owing to their excellent 
photophysical and biophysical properties, have been employed for CPNs have gained 
many recent attentions for microscopic cell/tissue imaging,10-13 biological sensing14-19, 
and nucleic acid delivery.20-22 Recently, we demonstrated that subtle CPN side-chain and 
backbone modifications significantly influence the cellular behaviors including toxicity, 
entry mechanism, and subcellular localization.  
Herein we report CPN-1 (Figure 4.1), a disulfide linker-containing poly(phenylene 
ethynylene) with TPP side-chains exhibiting mitochondria-specific co-localization. To 
obtain the fluorescent properties comparable to a fully conjugated PPE, the amount of 
disulfide monomer in the PPE backbone was maintained less than 50%.  Using a fully 
conjugated PPE, CPN-2 was also fabricated to support the concept that the degradability 
of CPNs is a crucial part for high intracellular organelle targeting.    
 
 F
ba
as
 
4
H
n
in
in
d
cy
pu
(F
F
en
P
ev
co
en
igure 4.1. Che
ckbone. CPN
sembly.    
.3. Resul
uman cervi
on-degradab
cubated wi
hibition up
ecrease) (se
tosolic com
nctuated pa
igure 4.2).  
or analyzing
dosome, an
earson's Co
aluation. P
rrelated co
tire cell w
mical structu
-1 (x:y=3:2) a
ts and Disc
cal carcinom
le CPN-2 f
th CPNs w
 to 40 µM
e Supportin
partment (
ttern, the flu
 subcellular
d mitochon
rrelation C
CC scores 
lors, respect
ere selecte
res of TPP-co
nd CPN-2 (x:
ussion 
a (HeLa) c
or overnight
as measur
, while CP
g Informatio
Figure 4.2).
orescent pa
 localization
dria) were p
oefficient 
of 0 and 1
ively. Mean
d and anal
85 
ntaining PPEs
y=1:0) were f
ells were in
, respective
ed by MTT
N-2 exhib
n). CPNs w
 Unlike to 
ttern of CPN
s of CPNs,
ost-stained 
(PCC) was
 correspond
 PCC score
yzed to inc
 with and wit
abricated with
cubated wit
ly. The met
 assay. C
its a slight
ere taken u
CPN-2, wh
-1 was som
 various org
using comm
 used to 
 to uncorre
s from thre
rease the 
hout biodegra
 the correspon
h biodegrad
abolic activ
PN-1 exhib
 inhibition 
p by cells 
ich exhibits
ewhat diffu
anelles (i.e
ercially av
quantitative
lated and p
e independe
analysis obj
dable linkers 
ding PPEs vi
able CPN-1
ity of HeLa
its no via
(~10% via
and found i
 a characte
sed and gra
., nucleus, G
ailable dyes
 co-localiz
erfectly lin
nt images 
ectivity. C
in the 
a self-
 and 
 cells 
bility 
bility 
n the 
ristic 
nular 
olgi, 
. The 
ation 
early 
of an 
PN-1 
 ex
en
M
m
th
qu
m
F
fo
 
T
ch
ce
fl
w
hibited alm
dosome (0.
eanwhile, C
itochondria
e mitochon
antitative l
itochondria
igure 4.2. Mic
llowed by mit
his dramati
ains (i.e., 
llular entry
exible linke
ith CPs with
ost exclusi
25) and Gol
PN-2 show
l and Golgi 
drial fractio
ocalization o
 and cytosol
roscopic imag
ochondrial (red
c subcellula
TPP) impli
 routes and
rs tend to f
out the flex
ve mitocho
gi apparatu
ed high en
apparatus c
n of Hela c
f CPN-1 in
ic fractions,
es of HeLa ce
) and nuclear 
r localizati
es that self
 the intrac
orm aggreg
ibility. Beca
86 
ndrial co-lo
s (0.23) co-l
dosomal co
o-localizatio
ells incuba
 mitochond
 respectively
lls incubated w
(blue) staining
on differen
-assembly 
ellular fates
ates with h
use of the fl
calization 
ocalizations
-localization
n (Figure 4
ted with CP
ria. Fluoresc
, were com
ith CPNs. Ce
. The scale ba
ce between
structures o
. We prev
igh interpol
exible disul
(PCC 0.89)
 were obser
 (PCC 0.7
.3). Fluoresc
Ns also cle
ent intensit
pared.     
lls treated with
r is 20 μm.  
 CPNs with
f CPNs po
iously foun
ymer intera
fide bonds, 
, while min
ved (Figure
6) with min
ence analy
arly suppor
ies at 495 n
 CPNs for 18
 the same
ssibly influ
d that CPs 
ctions comp
therefore, th
imal 
 4.3). 
imal 
sis of 
t the 
m of 
 
 hours 
 side 
ence 
with 
ared 
e  
 F
m
A
an
 
su
su
ph
fo
A
d
ca
al
cu
cl
igure 4.3. Qua
itochondria an
NOVA-Tukey
d mitochondri
rface prope
bsequent c
armacologi
r 2 hours an
s shown in
etermined b
veolae-med
so noticeab
rrently und
osely relate
ntitative co-lo
d endosome lo
 test demonstr
a. * p<0.0005
rties of CPN
ellular entry
cal inhibito
d mean fluo
 Figure 4.4
y the reduc
iated endoc
ly reduced
erway, we 
d to a series 
calization anal
calization, re
ate statisticall
.  
-1 will be 
. To test 
rs of variou
rescent inte
, CPNs use
ed uptake o
ytosis (CvM
. Although
speculate th
of cellular p
87 
ysis using the
spectively. The
y different CP
different an
endocytosis 
s endocytos
nsity of cell
 various en
f CPNs un
E), uptake 
 further m
at the high 
rocesses of 
 PCC algorithm
 error bar rep
N-1 and CPN
d influential
pathways, 
is pathways
s were moni
docytosis p
der the inhi
of CPN-1 v
echanistic 
mitochondr
MPC intern
 
. CPN-1 and
resents ±stand
-2 co-localiza
 for cellular
HeLa cells
 were incub
tored by flo
athways to 
bitors teste
ia macropi
and traffick
ia localizat
alization of 
 CPN-2 exhibi
ard deviation 
tion with end
 interaction
 pretreated 
ated with C
w cytometry
enter HeLa
d. In additio
nocytosis (M
ing studies
ion of CPN
CPN-1,  
t high 
(n=3).  
osome 
s and 
with 
PNs 
.    
 cell, 
n to 
PC) 
 are 
-1 is 
 F
en
flu
(2
cy
de
 
d
en
d
p
T
d
fu
im
b
th
igure 4.4. En
docytosis inh
orescent inten
10 μM, CvM
tochalasin D 
viation. *p < 0
egradation o
dosomes an
iffusion to t
athway as th
o determine
egradation k
nction of t
aging, with
etween CPN
ree indepen
docytosis pa
ibition measu
sity of HeLa 
E), methyl-β-
(0.04 mM, M
.05 when com
f disulfide b
d macropin
rafficking to
e macropino
 whether th
inetics, we
ime. Subce
 CPNs incu
 and mitoch
dent trials 
thways of TP
rements of 
cell (Control),
cyclodextrin (
PC) were me
pared between
onds to gen
osomes due
 mitochond
somes are n
e observed
 measured 
llular locali
bated for 3
ondrial or e
(Figure 4.5)
88 
P-containing 
CPNs under 
 CPNs only (C
1000 mM, C
asured using 
 polymers CP
erate low m
 to increase
ria. MPC i
on-acidic a
 CPN-1 mi
endosome 
zation was 
, 6, 12, and
ndosomal m
. CPN-1 ex
CPNs. Aver
pharmacologi
PN), chlorpro
vME/MPC), L
flow cytomet
N-1 and CPN-
olecular we
d hydropho
s known as
nd leaky. 
tochondrial 
and mitoch
monitored 
 18 hours 
arkers was 
hibited a ti
age of three 
cal inhibitors
mazine (24 m
Y294002 (12
ry. Error bars
2.  
ight COs, b
bicity of CO
 a relatively
specificity 
ondrial co-l
by fluoresc
in HeLa ce
measured an
me-depende
 
independent 
 treatments. 
M, CME), gen
0 μM, MPC
 represent sta
etter escapi
s, and incre
 non-destru
is related t
ocalization 
ent micros
lls. PCC sc
d averaged 
nt mitochon
(n=3) 
Mean 
istein 
), and 
ndard 
ng of 
ased 
ctive 
o the 
as a 
copic 
oring 
from 
drial 
89 
 
and endosomal co-localization. As incubation time increased, CPN-1 localized more 
strongly towards the mitochondria, with almost exclusive mitochondrial localization at 18 
hours incubation. CPN-2, meanwhile, did not show time-dependent co-localization, 
exhibiting no significant change in mitochondrial or endosomal localization as incubation 
time increased. Although CPN-2 has high mitochondria targeting TPPs, the non-
degradability, large molecular weight, and poor endosome escaping and diffusion 
efficiency of CPN-2 limit mitochondria targeting. The time-dependency of CPN-1 on co-
localization supports that degradation of biodegradable linkers play a significant role in 
mitochondrial trafficking of TPP functionalized COs. 
4.4.  Conclusion  
We present here a new strategy to achieve a unique time-dependent mitochondrial-
specific localization of CPNs. We demonstrated that disulfide-containing CPN exhibits 
active cellular internalization as polymer nanoparticles via a variety of endocytosis, and 
undergoes degradation to actively trafficking to the mitochondria as low molecular 
weight oligomers. The concept we demonstrated here will lead to the development of 
novel polymeric materials for improved intracellular targeting and drug delivery 
efficiency. Currently, we are performing in vivo studies including pharmacokinetics and 
biodistribution, fine-tuning of degradation kinetics, and targeted delivery of drugs to 
mitochondria. 
4.5.     Outlook   
Since the writing of this chapter, a several non-flexible-containing TPP copolymers were 
synthesized and screened for mitochondrial-specificity. Preliminary results indicate the 
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semi-flexible linker plays a key role in the mitochondrial-specificity exhibited by CPN-1. 
Because the key towards the mitochondrial-specificity appears to be the biodegradable 
linker, a variety of applications for sensing and delivery emerge by covalent 
incorporation of oxygen species (ROS)-sensitive attachment to the CPN. However, the 
role that molecular weight play in the mitochondrial-specificity has yet to be explored. 
Additionally, whether the CPN localizes on the outer or inner mitochondrial membrane 
or mitochondrial lumen, remains to be determined. Successful development of 
mitochondria-specific fluorescent label, delivery vehicle, or (ROS) sensors, will depend 
on the fate of the CPN. Finally, determination of the precise mechanism by which the 
CPN undergoes endosomal escape will facilitate optimization and development of future 
CPN polymers.  In conclusion, the understanding the role that the semi-flexible linker 
plays in the CPN degradation within the cell, and the resulting subcellular distribution, 
will continue to facilitate development of novel multifunctional materials for labelling, 
sensing, and delivery. 
4.6 Experimental Section 
Polymer synthesis and characterization was carried out by Dr. Rajesh Kumar Manian. 
Toxicity assay was carried out by Yong Myoung.  
 
4.6.1.  General Information. 
Chemicals, including solvents, were purchased from Fisher Scientific and used as 
received. Deuterated solvents were purchased from Cambridge Isotope Laboratories 
(Cambridge, MA). UV-vis spectra were recorded using a Varian Cary 50 Bio 
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spectrophotometer. Fluorescence spectra were obtained using a FluoroLog-3 
Spectrofluorometer (Jobin Yvon/Horiba). 9, 10-diphenylanthracene (QY = 1.0) in 
cyclohexane was used as a fluorescence standard for QY determination. The average 
molecular weight (Mn) and polydispersity (PDI = Mw/Mn) of the polymers were 
determined by gel permeation chromatography (GPC) against polystyrene standards 
using a Shimadzu high performance liquid chromatography (HPLC) system fitted with 
PLgel 5 μm  MIXED‐D  columns  and  SPD‐20A  ultraviolet−visible (UV−vis) detector. 
Nuclear magnetic resonance (NMR) spectra were recorded on a 400 MHz Avance Bruker 
NMR spectrometer. 1H and 13C NMR chemical shifts are given in ppm relative to 
Si(CH3)4, with the solvent resonance used as internal reference. 1H NMR on the 
δ scale based on the middle peak (δ = 2.50 ppm) of the dimethyl sulfoxide DMSO-d6 
solvent as an internal standard or 7.26 ppm for chloroform (CDCl3) experiments. 31P 
NMR chemical shifts are reported in ppm relative to H3PO4. The mass spectrometric data 
were obtained at the mass spectrometry facility of the Florida International University. 
Analytical thin layer chromatography (TLC) was performed on TLC Silica gel 60 F254. 
The TLC plates were visualized by shortwave (254 nm) or longwave (360 nm) UV light. 
Flash chromatography on silica gel (230–400 mesh) was performed. Fourier transform 
infrared (FT-IR) spectrum was obtained on a PerkinElmer Spectrum 100 FT-IR 
Spectrometer; fine powder sample was mounted on an attenuated total reflection cell. 
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4.6.2. Monomer Synthesis. 
 
Scheme 4.1: 
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4.6.2.1 Synthesis of monomer 133 
1, 4-Dihydroxy-2, 5-diiodobenzene (5.00 g, 13.80 mmol) was dissolved in acetone (20 
mL) and the resulting solution was added slowly to a stirred suspension of K2CO3 (7.60 
g, 55.25 mmol) and NaI (8.30 g, 55.25 mmol). The reaction mixture was allowed to stir 
for 10 min followed by the slow addition of TEG-Cl (5.80 g, 34.53 mmol).  The reaction 
was heated to 80 ºC for 12 h. The solution was cooled to room temperature, the solvent 
was removed, and the resulting slurry was re-dissolved in CH2Cl2 (100 mL). The solution 
was extracted with water (100 mL x3) and the organic fractions were collected and 
concentrated in vacuo until an oily residue remained. The crude product was purified by 
silica gel chromatography (95:5 EA / Hexane). The product was off-white solid. Yield:  
5.80 g (67.0%). 1H NMR (400 MHz, CDCl3): δ 7.24 (s, 2H), 4.09- 4.15 (t, 4H), 3.86-3.92 
(t, 4H), 3.77-3.82 (m, 4H), 3.69-3.76 (m, 8H), 3.60-3.66 (m, 4H), 2.29 (br, 2H); 13C 
NMR (400 MHz, CDCl3): δ 153.51, 123.21, 86.52, 72.51, 71.22, 70.54, 70.28, 69.66, 
61.82. 
  
93 
 
4.6.2.2 Synthesis of monomer M134 
A suspension of compound 1 (5.00 g, 7.98 mmol) was dissolved in 25 mL of DCM 
carbon tetrabromide (8.00 g, 23.95 mmol) and triphenyl phosphine (12.60 g, 23.95 mmol) 
added slowly to the reaction mass. The mixture was stirred at room temperature for 2 h. 
The solvent was removed and the crude product was purified by column chromatography 
(1: 4 EA / Hexane). The product was white solid. Yield:  5.30 g (81.2%). 1H NMR (400 
MHz, CDCl3): δ 7.30 (s, 2H), 4.10-4.15 (t, 4H), 3.89-3.92 (t, 4H), 3.85-3.87 (t, 4H), 3.68-
3.76 (m, 4H), 3.60-3.65 (m, 4H), 3.45-3.51 (m, 4H). 13C NMR (400 MHz, CDCl3): δ 
153.37, 123.49, 86.47, 71.30, 71.19, 70.71, 70.33, 69.70, 30.42. 
Monomer 2 (M2) was synthesized according to literature procedure (Scheme 2)35. 
Scheme 4.2
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4.6.2.3 Synthesis of monomer M3. 
      Scheme 4.3: 
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M3  
 3,3'-Dithiodipropionic acid (1.00 g, 4.76 mmol) was dissolved in anhydrous 
tetrahydrofuran (20 mL) in a round bottom flask, which was evacuated and filled with 
nitrogen. N-methylmorpholine (0.90 g, 9.52 mmol) was added, and the suspension was 
allowed to stir until the entire solid was dissolved. Isobutyl chloroformate (1.30 g, 9.52 
mmol) was added, and the mixture was allowed to stir at room temperature for 15 min. A 
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solution of 4-ethynylaniline (1.10 g, 9.52 mmol) in anhydrous THF (10 mL) was 
prepared under a N2 atmosphere and transferred into the reaction flask using a cannula. 
The reaction was allowed to proceed overnight, after which the reaction mixture was 
filtered. The filtrate was concentrated in vacuo, and the resulting solid was precipitated 
overnight from the DCM / diethyl ether solvent system. Yield: 0.70 g (36.0%). 1H NMR 
(400 MHz, DMSO): δ 10.20 (s, 2H), 7.50-7.70 (d, 4H), 7.35-7.40 (d, 4H), 4.09 (s, 2H), 
2.95-3.10 (t, 4H), 2.62-2.78 (t, 4H). 13C NMR (400 MHz, DMSO): δ 169.53, 139.68, 
132.36, 118.94, 116.12, 83.49, 79.65, 36.08, 33.38. HRMS (ESI): Calcd for C22H20 
n2O2S2 [M+Na]+: 431.0858; found [M+Na]+ : 431.0801.  
4.6.3. Polymer Synthesis. 
General Procedure. A Schlenk flask was charged with monomer M1 (1.00 eqiv.), M2 
(0.5 eqiv.), M3 (0.5 eqiv.) Pd[(PPh3)2Cl2] (0.10 equiv.) and CuI (0.05 equiv.). The 
Schlenk flask was evacuated and filled with N2. A solution of anhydrous 
dimethylformamide (4 mL) and diisopropylamine (1 mL) was degassed, and 2.5 mL of 
the mixed solution was transferred to the Schlenk flask using a cannular needle. The 
reaction was allowed to stir at room temperature for 12 h. The solution was then 
transferred drop wise to methanol, resulting in precipitation. After centrifugation (3 min, 
4000 rpm), the supernatant was decanted, and the precipitate was redissolved in DCM (1 
mL) for further purification. 
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4.6.3.1 Synthesis of P1.  
Scheme 4.4: 
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P1-Br. Using general procedure described above, the polymerization of monomer M1 
(100 mg, 0.133 mmol), M2 (30 mg, 0.066 mmol) and M3 (28 mg, 0.066 mmol) in the 
presence of Pd[(PPh3)2Cl2] (9.3 mg, 0.013 mmol), and CuI (1.3 mg, 0.007 mmol). 
Resulting mixture was purified by precipitation in methanol (x3) Yield: 105 mg (42.5 %). 
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An aliquot was redissolved in THF and molecular weight obtained and photo physical 
properties characterized in DCM. 
P1-Br: GPC: Mw =13.66 kDa; Mn = 09.30 kDa; PDI = 1.42. UV-vis: λmax = 400 nm; fluo 
λmax = 467 nm; QY = 0.69% and ε = 42716.79 M-1 cm-1(Per repeating Unit) in DCM. 1H 
NMR (400 MHz, CDCl3): δ 8.25-8.50 (br, 2H), 7.50-7.65 (br, 4H), 7.39-7.52 (br, 4H), 
6.90-7.10 (br, 4H), 4.10-4.30 (br, 10H), 3.85-4.00 (br, 11H), 3.70-3.80 (br, 22 H), 3.60-
3.70 (br, 14H), 3.50-3.60 (br, 4H), 3.40-3.50 (br, 5H), 3.30-3.45 (br, 6H), 3.00-3.10 (br, 
3H) and 2.75-2.90 (br, 3H). FT-IR (neat): ν = 2924, 2868, 1671, 1589, 1512, 1408, 1352, 
1265, 1214, 1097, 1041, 937, 838 cm-1.  
4.6.3.2. Synthesis of P1. 
Triphenyl phosphine (141 mg, 0.540 mmol) was dissolved in chloroform and resulting 
solution was added to a stirred suspension of P1-Br (100 mg, 0.054 mmol). The reaction 
was heated to 85 ºC for 12 h. The resulting mixture was purified by precipitation in ethyl 
acetate (x5). Yield: 70 mg (44.7%). 
P1: UV-vis: λmax = 405 nm; fluo λmax = 472 nm; QY = 0.40% and ε = 67606.65 M-1cm-1 
(Per repeating Unit) in DMSO. 1H NMR (400 MHz, CDCl3): δ 7.98-8.10 (br, 2H), 7.40-
7.90 (br, 40H), 7.26-7.45 (br, 4H), 6.80-7.10 (br, 4H), 4.00-4.40 (br, 10H), 3.10-3.90 (br, 
65H), and 2.75-3.00 (br, 2H). FT-IR (neat): ν = 2921, 2870, 1683, 1597, 1520, 1430, 
1408, 1210, 1099, 1047 cm-1. 
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Scheme 4.5: 
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P2-Br. Using general procedure described above, the polymerization of monomer M1 
(100 mg, 0.133 mmol) and M2 (60.0 mg, 0.133 mmol) in the presence of Pd[(PPh3)2Cl2] 
(9.3 mg, 0.013 mmol), and CuI (1.3 mg, 0.007 mmol). Resulting mixture was purified by 
precipitation in methanol (x3) Yield: 0.15 g (88.5 %). An aliquot was redissolved in THF 
and molecular weight obtained and photo physical properties characterized in DCM. 
P2-Br: GPC: Mw = 26.36 kDa; Mn = 15.98 kDa; PDI = 1.65. UV-vis: λmax = 432 nm; fluo 
λmax = 473 nm; QY = 0.53% and ε = 23526.82 M-1 cm-1(Per repeating Unit) in DCM. 1H 
NMR (400 MHz, CDCl3): δ 7.05-7.10 (br, 4H), 4.25-4.30 (br, 8H), 3.87-3.95 (br, 9H), 
3.75-3.80 (br, 12H), 3.59-3.65 (br, 13H), 3.45-3.52 (br, 4H), 3.42-3.48 (4H), 3.35-3.38 
(br, 7H). FT-IR (neat): ν = 2923, 2870, 2197, 1510, 1423, 1270, 1241, 1092, 1060 cm-1. 
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4.6.3.4. Synthesis of P2. 
Triphenyl phosphine (270 mg, 1.02 mmol) was dissolved in chloroform and resulting 
solution was added to a stirred suspension of P2-Br (100 mg, 0.102 mmol). The reaction 
was heated to 85 ºC for 12 h. The resulting mixture was purified by precipitation in ethyl 
acetate (x5). Yield: 95 mg (61.7%). 
P2: UV-vis: λmax = 436 nm; fluo λmax = 478 nm; QY = 0.25% and ε = 46128.66 M-1 cm-
1(Per repeating Unit) in DMSO. 1H NMR (400 MHz, DMSO): δ 7.56-7.90 (br, 32H), 
7.02-7.12 (br, 4H), 6.98-7.00 (br, 1H), 4.15-4.30 (br, 8H), 3.80-3.95 (br, 4H), 3.72-3.79 
(br, 6H), 3.50-3.60 (br, 15H), 3.34-3.50 (br, 14H), 3.35-3.40 (br, 4H), 3.10-3.20 (br, 9H). 
FT-IR (neat): ν = 3393, 2874, 2190, 1625, 1493, 1437, 1420, 1353, 1207, 1102, 1046 cm-
1. 
4.6.4. Determination of zeta potentials of P1 and P2. 
 Dynamic light scattering measurements were performed by Zetasizer nano-ZS (Zen 
3600, Malvern Instruments Ltd.) using a folded capillary cell (Catalog # DTS1060), at 
room temperature. The samples were prepared at approximately 0.1 mM in a 5% DMSO 
(v/v) solution using deionized water (18 Ω), which was filtered through 0.45 μm PTFE 
syringe filter. Each sample was measured six times. 
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Figure 4.5. Zeta potential of P1  
 
Figure 4.6. Zeta potential of P2  
4.6.5 Toxicity Assay. 
 HeLa cells (ca. 10 000 cells per well) in 200 μL of complete medium were seeded into a 
96-well plate and cultured for one day in a 5% CO2 incubator at 37 °C. CPNs with 
various concentrations (1 to 40 μM) were added and incubated for 24 h. To measure 
toxicity, 10 μL of MTT solution (5 mg mL-1 in PBS) and 90 μL of complete medium 
were then added into each well, and the plate was further incubated for 4 h at 37 °C. After 
formed MTT formazan crystals were dissolved in dimethyl sulfoxide (100 μL), the 
 ab
T
co
m
 
 
4
N
A
4
sorbance i
ECAN, Sw
ncentration
easurement
.6.6 Light sc
anoparticle 
mesbury, U
88 nm blue
ntensity me
itzerland) a
 was expres
s were tripli
Figur
attering m
tracking an
nited Kingd
 laser, and 
asured by 
t 540 nm. 
sed as a pe
cated and st
e 4.7. Cellul
easurement
alysis (NTA
om), equipp
Viton fluor
101 
a micropla
Relative ce
rcentage re
andard devia
ar toxicity o
s of CPN-1
) were per
ed with a s
oelastomer 
te well rea
ll viability 
lative to the
tion was in
f CPN-1 an
 and CPN-2
formed wit
CMOS cam
o-ring. The
der (infinit
(%) as a f
 untreated 
cluded in th
d CPN-2 
.  
h a LM10 
era, sample
 samples w
e M1000 P
unction of 
control cell
e error bar.
HS (NanoS
 chamber w
ere prepare
RO, 
CPN 
s All 
  
ight, 
ith a 
d in 
102 
 
similar manner for absorption and emission measurements using 10% methanol (v/v) in 
water (18 Ω) filtered through 0.45 μm polytetrafluoroethylene (PTFE) syringe filters. The 
samples were injected into the sample chamber with 1 mL sterile syringes (Restek 
Corporation, Pennsylvania, USA) until the liquid reached the tip of the nozzle. All 
measurements were performed at 25°C using a LM14C temperature controller 
(NanoSight, Amesbury, United Kingdom). Each sample was measured three times. 
4.6.7 Cell Culture.  
General.  
HeLa cells (human cervical cancer, purchased from ATCC), seeded into a 100 x 20 mm 
style sterile tissue culture dish (#353003 BD Falcon, Durham, NC, USA), cultured in 
minimum essential medium (MEM)/Earle’s balanced salt solution (EBSS) (400 μL, 
HyClone, SH30024) medium containing 10% fetal bovine serum (FBS) and 100 U/m 
penicillin for 24 h under 5% CO2 at 37 °C, and subcultured every 48 hours. pHRhodo 
Dextran 10kDa (#P10361 Molecular probes, Life technologies, New York, USA) and 
BODIPY-TR C5 -ceramide-BSA complex (#B34400 Molecular probes, Life 
technologies, New York, USA) were used for endosome and Golgi apparatus staining, 
respectively.  
4.6.8 Microscopic Imaging.  
10,000 HeLa cells were seeded into a glass-bottomed eight-well chamber slide (Lab-Tek 
Thermo Scientific) and cultured in a minimum essential medium (MEM)/Earle’s 
balanced salt solution (EBSS) (400 μL) medium containing 10% fetal bovine serum 
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(FBS) and 100 U/m penicillin for 24 h under 5% CO2 at 37 °C. 80 μL of 20 μM CPNs in 
water was added to the culture medium directly, and the cells were further cultured 
overnight (final CPN concentration: 4 μM). For endosome staining, pHRhodo Dextran 
10kDa (5µM) was incubated for 30 min at 37oC. For Golgi apparatus staining, BODIPY-
TR C5 -ceramide-BSA complex (final 10 μM) was incubated for 30 min at 4 °C. After 
washing with fresh medium, the cells were further incubated for 30 min at 37 °C. A 1 μL 
aliquot of Hoechst (5 μg/mL) was added to the culture medium and incubated with the 
cells for 10 min at 37 °C, and washed two times with phosphate buﬀered saline (PBS). 
The cells were fixed with 4% paraformaldehyde for 10 min. Fluorescent images of the 
cells were obtained using a DeltaVision Elite Microscope System (Applied Precision, 
Issaquah, Washington, USA) equipped with bandpass filters such as blue (410−460 nm, 
Hoechst), green (500−550 nm, CPNs), and red (595-635 nm, Golgi and endosome). Top 
and bottom of the chosen cells was identified, and a Z-stack plot was imaged for each 
channel.  
4.6.9. Colocalization study.  
Z-stack microscope images of each sample was obtained as described above. 
Colocalization analysis was conducted for three independent cells per polymer and per 
organelle (Golgi apparatus and endosome). Colocalization analysis was conducted using 
the microscope software (Softworx 5.0 application, Applied Precision, Issaquah, 
Washington, USA). Region of interest (ROI) was selected to contain all of the cell. 
Pearsons Correlation Coefficient (PCC) was used to determine colocalization. Negative 
control of colocalization was performed by analysis of blue and green channels staining 
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the nucleus and CPN, respectively. Three independent images of an entire cell were 
selected and analysed to increase the analysis objectivity.  
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CHAPTER V 
 
CONTROLLED INCORPORATION OF 
HOMO-COUPLED BENZOTHIADIAZOLE TO THE  
CONJUGATED BACKBONE 
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5.1  Abstract 
We successfully controlled the incorporation of homo-coupled benzothiadiazole(HBT) 
blocks onto the conjugated polymer nanoparticle (CPN). This was achieved by 
employing competing polymerization conditions between the cross (i.e., Sonogashira) 
and homo-coupling reactions. Using these conditions we were able to synthesize a suite 
of polymers such as BT-containing poly-parapheneylene ethynelene (BTPEs), HBT-
containing PPE (HBT-PE), and BTPE-containing poly-parapheneylene butadiyene 
(BTPE-PPB), exhibiting a range of emissions. This advancement can result in the 
synthesis of new and exciting red-emissive polymers for tissue labeling and cellular 
sensing.  
5.2.  Introduction  
Conjugated polymer nanoparticles (CPNs) are promising fluorescent biomaterials 
exhibiting high brightness and efficient energy transfer making them suitable for cellular 
labelling and sensing applications.1 Various chemosensors have been reported that take 
advantage of the unique signal amplification or superquenching as the fluorescent CPN 
interacts with analytes of interest.2  Because of their conjugated nature, any interaction 
occurring along the polymeric backbone will result in the perturbation of the electron 
transport properties of the conjugated system affects the entire assembly. Additionally, 
CPNs exhibit aggregation based absorbance and emission changes, making CPN-based 
molecular probes sensitive even minor perturbations upon analyte-polymer interactions 
and binding.3 Therefore, a multitude of analyte-CPN interactions will result in large 
signal amplification due to the collective features of the CP. 4 
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For biological applications, synthesis of CPs exhibiting red emission is highly desirable 
as the sensitivity of any in vivo measurements and optical imaging is enhanced due to 
minimal autofluorescence from biological tissues at this range CPs that have incorporated 
electron donating and accepting moieties onto the conjugated backbone have been shown 
to effectively modulate the CP’s electronic properties resulting in red shifted emissions.5 
As an electron-accepting moiety, 2,1,3-Benzothiadiazole (BT) has been used in various 
oligomers and polymers, exhibiting orange to red emission, with higher incorporation of 
the BT units into the CP backbone improving absorption, thermal stability, 
electrochemical and charge transport properties of the resulting copolymers.6  Among 
BT-containing CPs, materials containing homo-coupled benzothiadiazole (HBT) 
segments in the conjugated backbone have been shown to further improve the materials 
optical and electronic properties.7 Despite these favorable properties, there have been few 
reports on the use of HBT-containing materials due to a lack of an efficient method for 
their synthesis. Most reports of HBT synthesize include time- and step-intensive methods 
involving the synthesis of 7,7'-dibromo-4,4'-bibenzo[c][1,2,5]thiadiazole which is then 
polymerized.8-9 However, copper-catalyzed oxidative addition under strong basic 
conditions has also been reported for HBT synthesis.10 
Recently, we reported the synthesis of flexible poly(p-phenylenebutadiynylene)s (PPBs) 
using competing Sonogashira and Glaser coupling conditions, and taking advantage of 
the differences in monomer reactivity to incorporate a small amount (~10%) of flexible, 
non-conjugated linkers into the backbone.11 The reaction conditions provide limited 
control over the proportion of flexible monomer incorporation, effectively affording 
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phenylene-ethynylene(PE)-doped PPBs. We hypothesized that by using competing 
Sonogashira and benzothiadiazole homo-coupling conditions, we could easily synthesize 
HBT-containing PPEs.   
Here we report a one-pot method for the controlled incorporation of HBT blocks onto the  
CP backbone. Using commercially available BT monomers, we were able to synthesize 
HBT-containing CPs without employing the time- and step-intensive methods usually 
employed to afford these polymers. Using this one-pot method, we successfully 
synthesized a suite of polymers such as BT-containing poly-parapheneylene ethynelene 
(BTPEs), HBT-containing PPE (HBT-PE), and BTPE-containing poly-parapheneylene 
butadiyene (BTPE-PPB), exhibiting a range of emissions.  
5.3.  Results and Discussion 
It was hypothesized that high copper content and increased base strength would facilitate 
HBT incorporation during the polymerization process. This is because HBT synthesis has 
been reported via copper-catalyzed oxidative addition under strong basic conditions, the 
modified coupling conditions. To create a competing environment between the cross (i.e., 
Sonogashira) and homo-coupling of the monomers, varying amounts of copper (5% or 
95% molar equivalents) catalyst and organic bases of increasing base strength 
(TEA>morpholine>Pyridine>K2CO3) were employed. The reactions were carried out in a 
nitrogen environment at 60°C in overnight using dimethylformamide as the 
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Scheme 5.1. Synthesis of HBT-BTPE and BTPE polymers 
 
Table 5.1. . List of polymer chemical structures at various reaction conditions 
Polymer CuI Pd(II) Base xa ya 
P1 5% 5% TEA 0 1 
P2 5% 5% Morpholine 0.12 1 
P3 5% 5% Pyridine 0.4 1 
P4 5% 5% K2CO3 0.7 1 
P5 95% 5% TEA 0.4 1 
P6 95% 5% Morpholine 0.8 1 
P7 95% 5% Pyridine 1.4 1 
P8 95% 5% K2CO3 2.4 1 
P9 2eq 5% K2CO3 2.4 1 
a Determined by 1H NMR peak integration. 
polymerization solvent, as outlined in Scheme 5.1. A series of polymers were prepared 
under these modified palladium/copper/base conditions as listed in Table 5.1.  
The chemical structure of the resulting polymers was assessed by 1H NMR spectroscopy. 
An example of the quantitative assessment of the presence HBT segments is illustrated 
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on the structure of polymer P4 (Figure 5.1). The 1H NMR spectrum clearly exhibits three 
distinct aromatic peaks at 7.95, 7.30, and 6.74 ppm corresponding to HBT, BT, and PE 
aromatic peaks, respectively. 2-dimensional NMR confirms that peak the peaks at 7.95 
and 7.30 ppm are both from a BT moiety. The integration ratio between the HBT 
(7.95ppm) and PE (6.74ppm) peaks indicates that the incorporation of the HBT-segments 
to the conjugated backbone was approximate 66%. Figure 5.2 demonstrated the 
increasing incorporation of HBT onto the conjugated backbone as demonstrated by the 
increasing size of the HBT aromatic peak increases as a function of base strength and 
copper catalyst loading. Full NMR spectra for all polymers are included in the 
Experimental Section.  
 
Figure 5.1. 1H-NMR for polymer P4 in DMSO-d6 
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Table 5.2. Physical and optical properties 
Polymer Yield (%) Mn 
(kDa)a 
PDIb Abs 
λmax 
(nm)c 
Em 
λmax 
(nm)e 
P1 65 13.5 1.69 454 571 
P2 71 10.3 1.95 497 595 
P3 40 12.4 1.76 502 633 
P4 48 12.7 1.75 494,553 620 
P5 67 14.5 1.89 500,551 621 
P6 54 8.52 1.92 551 640 
P7 62 14.5 1.89 553 646 
P8 57 8.52 1.92 552 651 
aDetermined by gel permeation chromatography in THF. b PDI (polydispersity index) = Mw/Mn. cMeasured 
in ACN. d P1,P2, P3 excitation wavelength 450 nm, P4-P8 excitation wavelength 500 nm in ACN. 
5.4.  Conclusion 
In conclusion, by creating a competing environment between the cross (i.e., Sonogashira) 
and homo-coupling of the monomers, we were able to synthesize HBT-containing CPs 
without employing the time- and step-intensive methods usually employed to afford these 
polymers. Additionally, we successfully synthesized a suite of polymers such as BT-
containing poly-parapheneylene ethynelene (BTPEs), HBT-containing PPE (HBT-PE), 
and BTPE-containing poly-parapheneylene butadiyene (BTPE-PPB), exhibiting a range 
of emissions. This advancement can result in the synthesis of new and exciting red-
emissive polymers for tissue labeling and cellular sensing.  
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molecular tin (Sn). Interestingly, as HBT-incorporation increased, tin sensitivity 
exponentially increased, with polymers P7 and P8 exhibiting low nanomolar and high 
picomolar sensitivity, respectively. Among the different metal ions, tin, has been 
established to be an essential trace element for some animals. Although tin is not easily 
absorbed by animals and humans, tin deficiency has been linked with poor growth, 
hearing loss, and increased cancer risk. Acute tin toxicity has been shown to affect iron 
and copper metabolism by interfering with heme and cytochrome P450. Because the role 
tin plays in biochemical processes at the cellular level remains largely unknown, there is 
great importance is attached to developing sensitive tin-specific chemosensors. In recent 
years, significant emphasis has been placed on the development of new, highly selective 
fluorescent chemosensors of different architectures for metal cations because of their 
potential applications in biochemistry and environmental research. Owing to their 
excellent photophysical and biophysical properties, CPNs are rapidly emerging as an 
exciting fluorescent platform for sensitive biological sensing. 
5.5. Experimental Section 
5.5.1. General Data. Chemicals, including solvents, were purchased from Fisher 
Scientific and used as received. Deuterated solvents were purchased from Cambridge 
Isotope Laboratories (Cambridge,MA). UV−vis spectra were recorded using a Varian 
Cary 50 Bio spectrophotometer. Fluorescence spectra were obtained using a FluoroLog-3 
Spectrofluorometer (Jobin Yvon/ Horiba). 9,10-diphenylanthracene (QY = 1.0) in 
cyclohexane was used as a fluorescence standard for QY determination. The average 
molecular weight (Mn) and polydispersity index (PDI = Mw/Mn) of the polymers were 
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determined by gel permeation chromatography (GPC) against polystyrene standards 
using a Shimadzu high performance liquid chromatography (HPLC) system fitted with 
PLgel 5 μm MIXED-D columns and SPD-20A ultraviolet− visible (UV−vis) detector. 
Nuclear magnetic resonance (NMR) spectra were recorded on a 400 MHz and 600 MHz 
Avance Bruker NMR spectrometer. Chemical shifts were reported in parts per million 
(ppm) for 1H-NMR on the δ scale based on the middle peak (δ = 2.50 ppm) of the 
dimethyl sulfoxide (DMSO)-d6 solvent as an internal standard. Solutions of Tables and 
graphs were plotted using Origin 8 software (OriginLab, Northampton, MA, USA).  
5.5.2 Polymer Synthesis.  
General Procedure. A Schlenk flask was charged with aryl halide monomer A (1.0 eqiv) 
and diactylene monomer B (1.0 equiv), along with Pd[(PPh3)2Cl2] (0.1 equiv) and CuI 
(0.05 or 0.95 equiv). The Schlenk flask was evacuated and filled with N2 three times. A 
solution of anhydrous dimethylformamide (DMF) (4 mL) and freshly distilled 
trimethylamine (1 mL) was degassed, and 1 mL of the mixed solution was transferred to 
the Schlenk flask using a cannular needle. The reaction was heated at 70 °C for14 h. The 
solution was then cooled to room temperature and transferred dropwise to cold methanol, 
resulting in precipitation. After centrifugation (2 min, 4000 rpm), the supernatant was 
decanted, and the precipitate was redissolved in DCM(1 mL) for and precipitated two 
more times for purification. The resulting precipitate was then dried under high vacuum 
for 2 days, weighed and characterized.  
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Scheme 5.2. Generalized scheme for BTPE-PPB formation 
 
Table 5.3. Chemical properties of P8, P10, and P11 
Polymer CuI Pd(II) Base x y z 
P8 95% 5% K2CO3 1.2 1 0 
P10 95% 10% K2CO3 0.15 1 0.45 
P11 95% 20% K2CO3 0 1 2.1 
 
Table 5.4. Physical and optical properties of P8, P10, and P11 
Polymer CuI Pd(II) Base Yield 
(%) 
Mn 
(kDa)
PDI Abs 
λmax 
(nm) 
Em 
λmax 
(nm) 
QY 
P9 2eq 5% K2CO3  37 13.5 1.97 540 671 5.0 
P10 95% 10% K2CO3  71 10.3 1.95 420,500 608 5.5 
P11 95% 20% K2CO3  40  12.4 1.76 400 525 3.6 
Mod 5% 5% K2CO3 41 9.87 1.81 500 622 3.1 
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P1. Using the general procedure described above, the polymerization of monomer 9 (32 
mg, 0.044 mmol) and monomer 13 (20 mg, 0.044 mmol) in the presence of 
Pd[(PPh3)2Cl2] (3 mg, 0.0044 mmol) and CuI (0.2 mg, 0.0022 mmol) yielded PPE 
polymer P-1 ( 32 mg, 71%). Molecular weight of boc-protected polymer was obtained 
and characterized. Resulting mixture was purified by precipitation in cold ethyl ether 
(x3). An aliquot was redissolved in THF and molecular weight obtained and photophycal 
properties characterized. The rest of the material was dissolved in DMSO-d6 and 
characterized using 1H-NMR.  
P1: GPC: Mw =22.82 kDa; Mn= 13.5 kDa; PDI = 1.69. UV λmax = 427 nm; fluo λmax(400 
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.31 (br, 1H, Bt-H), 6.74 
(br, 1H, Ph-H), 4.27 (br, 2H CH2OPh), 3.83 (br, 2H, OCH2), 3.56 (br, 2H, CH2O), 3.09 
(br, 2H, OCH2), 1.33 (s, 7H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w), 2935 
(m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m), 1363 
(s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m). 
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Figure 5.5. 1H-NMR for polymer P1 in DMSO-d6 
 
P2. Using the general procedure described above, the polymerization of 6 (30 mg, 0.056 
mmol) and monomer M2 (41 mg, 0.056 mmol) in the presence of Pd[(PPh3)2Cl2] (4 mg, 
0.0056 mmol) and CuI (0.3 mg, 0.0028 mmol) yielded PPE polymer P2 ( 44 mg, 73%). 
Resulting mixture was purified by precipitation in cold ethyl ether (x3). An aliquot was 
redissolved in THF and molecular weight obtained and photophycal properties 
characterized. The rest of the material was dissolved in DMSO-d6 and characterized 
using 1H-NMR. CPN formation was then carried out as described in general procedure to 
yield CPN-2 
 P2: GPC: Mw =20.09 kDa; Mn= 10.3 kDa; PDI = 1.95. UV λmax = 427 nm; fluo λmax(400 
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.95 (br, 0.12H, HBt-H), 
7.29 (br, 1H, Bt-H), 6.74 (br, 1H, Ph-H), 4.27 (br, 2H CH2OPh), 3.85 (br, 2H, OCH2), 
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3.09 (br, 2H, OCH2), 1.32 (s, 8H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w), 
2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m), 
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m). 
 
Figure 5.6. 1H-NMR for polymer P2 in DMSO-d6 
 
P3. Using the general procedure described above, the polymerization of monomer 4 (65 
mg, 0.054 mmol) and monomer 13 (32 mg, 0.054 mmol) in the presence of 
Pd[(PPh3)2Cl2] (8 mg, 0.0054 mmol) and CuI (0.4 mg, 0.0022 mmol) yielded PPE 
polymer P3 ( 45 mg, 61%). Resulting mixture was purified by precipitation in cold ether 
(x3). An aliquot was redissolved in THF and molecular weight obtained and photophycal 
properties characterized. The rest of the material was dissolved in DMSO-d6 and 
characterized using 1H-NMR.  
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P3: GPC: Mw =21.82 kDa; Mn= 12.4 kDa; PDI = 1.76. UV λmax = 427 nm; fluo λmax(400 
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.95 (t, 0.37H, HBt-H), 
7.30 (br, 1H, Bt-H), 6.74 (br, 1H, Ph-H), 4.28 (br, 2H CH2OPh), 3.86 (br, 2H, OCH2), 
3.11 (br, 3H, OCH2), 1.33 (s, 10H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w), 
2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m), 
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m). 
 
Figure 5.7. 1H-NMR for polymer P3 in DMSO-d6 
 
P4: GPC: Mw =22.23 kDa; Mn= 12.7 kDa; PDI = 1.75. UV λmax = 427 nm; fluo λmax(400 
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.95 (t, 0.6H, HBt-H), 
7.30 (br, 1H, Bt-H), 6.74 (br, 1H, Ph-H), 4.28 (br, 2H CH2OPh), 3.86 (br, 2H, OCH2), 
3.12 (br, 2H, OCH2), 1.33 (s, 8H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w), 
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2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m), 
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m). 
 
Figure 5.8. 1H-NMR for polymer P4 in DMSO-d6 
 
P5: GPC: Mw =27.41 kDa; Mn= 14.5 kDa; PDI = 1.89. UV λmax = 427 nm; fluo λmax(400 
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.95 (t, 2.3H, HBt-H), 
7.30 (br, 1H, Bt-H), 6.74 (br, 1H, Ph-H), 4.28 (br, 2H CH2OPh), 3.86 (br, 2H, OCH2), 
3.12 (br, 2H, OCH2), 1.33 (s, 8H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w), 
2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m), 
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m). 
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Figure 5.9. 1H-NMR for polymer P5 in DMSO-d6 
 
P6: GPC: Mw =16.36 kDa; Mn= 8.52 kDa; PDI = 1.92. UV λmax = 427 nm; fluo λmax(400 
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.95 (t, 0.7H, HBt-H), 
7.30 (br, 1H, Bt-H), 6.75 (br, 1H, Ph-H), 4.28 (br, 2H CH2OPh), 3.86 (br, 2H, OCH2), 
3.13 (br, 2H, OCH2), 1.33 (s, 8H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w), 
2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m), 
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m). 
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Figure 5.10. 1H-NMR for polymer P6 in DMSO-d6 
 
P7: GPC: Mw =27.41 kDa; Mn= 14.5 kDa; PDI = 1.89. UV λmax = 427 nm; fluo λmax(400 
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.95 (t, 0.7H, HBt-H), 
7.30 (br, 1H, Bt-H), 6.75 (br, 1H, Ph-H), 4.28 (br, 2H CH2OPh), 3.86 (br, 2H, OCH2), 
CH2O), 3.13 (br, 2H, OCH2), 1.33 (s, 7H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 
(w), 2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 
(m), 1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m). 
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Figure 5.11. 1H-NMR for polymer P7 in DMSO-d6 
 
P8: GPC: Mw =14.7 kDa; Mn= 7.75 kDa; PDI = 1.90. UV λmax = 427 nm; fluo λmax(400 
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.95 (t, 2.3H, HBt-H), 
7.30 (br, 1H, Bt-H), 6.74 (br, 1H, Ph-H), 4.28 (br, 2H CH2OPh), 3.86 (br, 2H, OCH2), 
3.12 (br, 2H, OCH2), 1.33 (s, 8H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w), 
2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m), 
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m). 
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Figure 5.12. 1H-NMR for polymer P8 in DMSO-d6 
 
P9: GPC: Mw =13.49 kDa; Mn= 6.85 kDa; PDI = 1.97. UV λmax = 427 nm; fluo λmax(400 
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.95 (t, 2.3H, HBt-H), 
7.30 (br, 1H, Bt-H), 6.74 (br, 1H, Ph-H), 4.28 (br, 2H CH2OPh), 3.86 (br, 2H, OCH2), 
3.12 (br, 2H, OCH2), 1.33 (s, 8H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w), 
2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m), 
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m). 
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Figure 5.13. 1H-NMR for polymer P9 in DMSO-d6 
 
P10: GPC: Mw =24.43 kDa; Mn= 16.4 kDa; PDI = 1.49. UV λmax = 427 nm; fluo λmax(400 
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.96 (t, 0.3H, HBt-H), 
7.31 (br, 0.7H, Bt-H), 6.74 (br, 1H, Ph-H), 4.26 (br, 2H CH2OPh), 3.84 (br, 2H, OCH2), 
3.48 (br, 2H, CH2O), 3.07 (br, 2H, OCH2), 1.33 (s, 8H, OC(CH3)3). FT-IR (Neat): ν = 
3372 (br), 2982 (w), 2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 
1425 (m), 1393 (m), 1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 
(m). 
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Figure 5.14. 1H-NMR for polymer P10 in DMSO-d6 
 
P11: GPC: Mw =24.43 kDa; Mn= 16.4 kDa; PDI = 1.49. UV λmax = 427 nm; fluo λmax(400 
nm ex) =471 nm; QY = 41% in DMF. 1H-NMR(400 MHz) : δ = 7.30 (br, 0.3H, Bt-H), 
6.74 (br, 1H, Ph-H), 4.27 (br, 2H CH2OPh), 3.83 (br, 2H, OCH2), 3.56 (br, 2H, CH2O), 
3.09 (br, 2H, OCH2), 1.33 (s, 9H, OC(CH3)3). FT-IR (Neat): ν = 3372 (br), 2982 (w), 
2935 (m), 2875 (s), 1710 (vs; C=O), 1513 (vs), 1461 (w), 1425 (m), 1425 (m), 1393 (m), 
1363 (s), 1276 (s), 1219 (s), 1172 (m), 1120 (m), 1060 (m), 1033 (m). 
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Figure 5.15. 1H-NMR for polymer P11 in DMSO-d6 
 
Polymer Characterization. Confirmed using 1H-NMR data by looking at characteristic 
aromatic peak for homo-coupled benzothiadizole (7.97ppm), phenylene ethynylene-
coupled benzothiaidzole (7.31), and phenylene (6.74) protons. IR samples were prepared 
by lyophilization to prepare neat sample. IR scans from 4000 to 700 cm-1 are presented 
below, depicting absence of boc-carbonate group and confirming deprotection. 
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